Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


Articles published in Lung Cancer

Retrieve available abstracts of 532 articles:
HTML format
Text format



Single Articles


    August 2019
  1. SHOJI F, Takeoka H, Kozuma Y, Toyokawa G, et al
    Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Lung Cancer. 2019;136:45-51.
    PubMed     Text format     Abstract available


  2. GAUVAIN C, Vauleon E, Chouaid C, Le Rhun E, et al
    Erratum to "Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases" [Lung Cancer 116 (February 2018) 62-66].
    Lung Cancer. 2019 Aug 14. pii: S0169-5002(18)30595.
    PubMed     Text format    


  3. LEE GJ, Lee H, Woo IS, Kim T, et al
    Erratum to "High expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors" [Lung Cancer 132 (June) (2019) 9-16].
    Lung Cancer. 2019 Aug 13. pii: S0169-5002(19)30554.
    PubMed     Text format    


  4. MAISONNEUVE P, Iavicoli S, Veronesi G
    Response to comment on: "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
    Lung Cancer. 2019 Aug 4. pii: S0169-5002(19)30574.
    PubMed     Text format    


  5. TANG W, Li X, Xie X, Sun X, et al
    EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Lung Cancer. 2019;136:6-14.
    PubMed     Text format     Abstract available


  6. HARAGAN A, Field JK, Davies MPA, Escriu C, et al
    Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
    Lung Cancer. 2019;134:79-84.
    PubMed     Text format     Abstract available


  7. ZUGAZAGOITIA J, Gomez-Rueda A, Jantus-Lewintre E, Isla D, et al
    Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Lung Cancer. 2019;134:72-78.
    PubMed     Text format     Abstract available


  8. GHIMIRE B, Maroni R, Vulkan D, Shah Z, et al
    Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme.
    Lung Cancer. 2019;134:66-71.
    PubMed     Text format     Abstract available


  9. BOUSEMA JE, van Dorp M, Hoeijmakers F, Huijbregts IA, et al
    Guideline adherence of mediastinal staging of non-small cell lung cancer: A multicentre retrospective analysis.
    Lung Cancer. 2019;134:52-58.
    PubMed     Text format     Abstract available


  10. HELLYER JA, Stehr H, Das M, Padda SK, et al
    Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Lung Cancer. 2019;134:42-45.
    PubMed     Text format     Abstract available


  11. VAN DE VEN M, Retel VP, Koffijberg H, van Harten WH, et al
    Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands.
    Lung Cancer. 2019;134:34-41.
    PubMed     Text format     Abstract available


  12. MELOSKY B, Juergens R, McLeod D, Leighl N, et al
    Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Lung Cancer. 2019;134:259-267.
    PubMed     Text format     Abstract available


  13. BOADA M, Guzman R, Montesinos M, Libreros A, et al
    UPSTAGING, CENTRALITY AND SURVIVAL IN EARLY STAGE NON-SMALL CELL LUNG CANCER VIDEO-ASSISTED SURGERY.
    Lung Cancer. 2019;134:254-258.
    PubMed     Text format     Abstract available


  14. BALATA H, Evison M, Sharman A, Crosbie P, et al
    CT screening for lung cancer: Are we ready to implement in Europe?
    Lung Cancer. 2019;134:25-33.
    PubMed     Text format     Abstract available


  15. ACKERMANN CJ, Reck M, Paz-Ares L, Barlesi F, et al
    First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
    Lung Cancer. 2019;134:245-253.
    PubMed     Text format     Abstract available


  16. VANNITAMBY A, Hendry S, Irving L, Steinfort D, et al
    Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.
    Lung Cancer. 2019;134:233-237.
    PubMed     Text format     Abstract available


  17. FRANCAVIGLIA I, Magliacane G, Lazzari C, Grassini G, et al
    Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Lung Cancer. 2019;134:225-232.
    PubMed     Text format     Abstract available


  18. LIU Z, Liang H, Lin J, Cai X, et al
    The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer.
    Lung Cancer. 2019;134:218-224.
    PubMed     Text format     Abstract available


  19. CAPELLETTO E, Migliorino MR, Morabito A, Chiari R, et al
    Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.
    Lung Cancer. 2019;134:210-217.
    PubMed     Text format     Abstract available


  20. YOSHIMURA K, Inoue Y, Karayama M, Tsuchiya K, et al
    Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
    Lung Cancer. 2019;134:202-209.
    PubMed     Text format     Abstract available


  21. DING PN, Becker TM, Bray VJ, Chua W, et al
    The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Lung Cancer. 2019;134:187-193.
    PubMed     Text format     Abstract available


  22. KASAHARA N, Kaira K, Yamaguchi K, Masubuchi H, et al
    Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer.
    Lung Cancer. 2019;134:180-186.
    PubMed     Text format     Abstract available


  23. DIETEL M, Savelov N, Salanova R, Micke P, et al
    Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
    Lung Cancer. 2019;134:174-179.
    PubMed     Text format     Abstract available


  24. OWEN DH, Williams TM, Bertino EM, Mo X, et al
    Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
    Lung Cancer. 2019;134:167-173.
    PubMed     Text format     Abstract available


  25. TAN KS
    Misclassification of the actual causes of death and its impact on analysis: A case study in non-small cell lung cancer.
    Lung Cancer. 2019;134:16-24.
    PubMed     Text format     Abstract available


  26. HYUN MH, Lee ES, Eo JS, Kim S, et al
    Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer.
    Lung Cancer. 2019;134:158-166.
    PubMed     Text format     Abstract available


  27. KIM H, Goo JM, Paeng JC, Kim YT, et al
    Evaluation of maximum standardized uptake value at fluorine-18 fluorodeoxyglucose positron emission tomography as a complementary T factor in the eighth edition of lung cancer stage classification.
    Lung Cancer. 2019;134:151-157.
    PubMed     Text format     Abstract available


  28. MANJUNATH Y, Upparahalli SV, Suvilesh KN, Avella DM, et al
    Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer.
    Lung Cancer. 2019;134:147-150.
    PubMed     Text format     Abstract available


  29. GIBSON AJW, Li H, D'Silva A, Elegbede AA, et al
    Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study.
    Lung Cancer. 2019;134:141-146.
    PubMed     Text format     Abstract available


  30. DAFNI U, Tsourti Z, Vervita K, Peters S, et al
    Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Lung Cancer. 2019;134:127-140.
    PubMed     Text format     Abstract available


  31. SANTO A, Pilotto S, Galetta D, Grossi F, et al
    Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.
    Lung Cancer. 2019;134:121-126.
    PubMed     Text format     Abstract available


  32. ZHANG B, Niu X, Zhang Q, Wang C, et al
    Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Lung Cancer. 2019;134:108-116.
    PubMed     Text format     Abstract available


  33. NAKAMURA H, Sugano M, Miyashita T, Hashimoto H, et al
    Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells.
    Lung Cancer. 2019;134:100-107.
    PubMed     Text format     Abstract available


  34. HAYASHI H, Iihara H, Hirose C, Fukuda Y, et al
    Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
    Lung Cancer. 2019;134:1-6.
    PubMed     Text format     Abstract available


  35. MAISONNEUVE P, Rampinelli C, Bertolotti R, Misotti A, et al
    Corrigendum to "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos" [Lung Cancer, 131 (May) (2019) 23-30].
    Lung Cancer. 2019;134:279.
    PubMed     Text format    


  36. CHOE EA, Cha YJ, Kim JH, Pyo KH, et al
    Dynamic changes in PD-L1 expression and CD8(+) T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
    Lung Cancer. 2019;136:30-36.
    PubMed     Text format     Abstract available


  37. WANG G, Ionescu DN, Lee CH, Hiruki T, et al
    PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.
    Lung Cancer. 2019;136:1-5.
    PubMed     Text format     Abstract available


    July 2019
  38. GRONDAHL V, Binderup T, Langer SW, Petersen RH, et al
    Erratum to "Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence" [Lung Cancer 132 (June) (2019) 141-149].
    Lung Cancer. 2019 Jul 31. pii: S0169-5002(19)30561.
    PubMed     Text format    


  39. BARBONE F, Barbiero F, Fasola G
    Correspondence regarding "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
    Lung Cancer. 2019 Jul 27. pii: S0169-5002(19)30564.
    PubMed     Text format    


  40. WANG X, Leader JK, Wang R, Wilson D, et al
    Erratum to "Vasculature surrounding a nodule: A novel lung cancer biomarker" [Lung Cancer 114 (December) (2017) 38-43].
    Lung Cancer. 2019 Jul 26. pii: S0169-5002(19)30560.
    PubMed     Text format    


  41. STEFFENS CC, Elender C, Hutzschenreuter U, Dille S, et al
    Corrigendum to "Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study" [Lung Cancer 130 (2019) (April) 216-225].
    Lung Cancer. 2019 Jul 22. pii: S0169-5002(19)30555.
    PubMed     Text format    


  42. AWAD MM, Leonardi GC, Kravets S, Dahlberg SE, et al
    Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
    Lung Cancer. 2019;133:96-102.
    PubMed     Text format     Abstract available


  43. PETERS S, Felip E, Dafni U, Belka C, et al
    Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
    Lung Cancer. 2019;133:83-87.
    PubMed     Text format     Abstract available


  44. LI X, Zhang C, Sun Z, Yang F, et al
    Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
    Lung Cancer. 2019;133:75-82.
    PubMed     Text format     Abstract available


  45. TSAKONAS G, Botling J, Micke P, Rivard C, et al
    c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.
    Lung Cancer. 2019;133:69-74.
    PubMed     Text format     Abstract available


  46. MORABITO A, Piccirillo MC, Maione P, Luciani A, et al
    Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.
    Lung Cancer. 2019;133:62-68.
    PubMed     Text format     Abstract available


  47. DIMOU A, Bamias A, Gogas H, Syrigos K, et al
    Inhibition of the Hedgehog pathway in lung cancer.
    Lung Cancer. 2019;133:56-61.
    PubMed     Text format     Abstract available


  48. MELOSKY B, Bradbury P, Tu D, Florescu M, et al
    Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group
    Lung Cancer. 2019;133:48-55.
    PubMed     Text format     Abstract available


  49. SAKIN A, Sahin S, Yasar N, Demir C, et al
    Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy.
    Lung Cancer. 2019;133:38-44.
    PubMed     Text format     Abstract available


  50. LOWENSTEIN M, Vijayaraghavan M, Burke NJ, Karliner L, et al
    Real-world lung cancer screening decision-making: Barriers and facilitators.
    Lung Cancer. 2019;133:32-37.
    PubMed     Text format     Abstract available


  51. AREDO JV, Padda SK, Kunder CA, Han SS, et al
    Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
    Lung Cancer. 2019;133:144-150.
    PubMed     Text format     Abstract available


  52. SHINDE A, Horne ZD, Li R, Glaser S, et al
    Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
    Lung Cancer. 2019;133:136-143.
    PubMed     Text format     Abstract available


  53. DEGENS JHRJ, Sanders KJC, de Jong EEC, Groen HJM, et al
    The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.
    Lung Cancer. 2019;133:130-135.
    PubMed     Text format     Abstract available


  54. ROMERO-VIELVA L, Viteri S, Moya-Horno I, Toscas JI, et al
    Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer.
    Lung Cancer. 2019;133:117-122.
    PubMed     Text format     Abstract available


  55. KSIENSKI D, Wai ES, Croteau N, Freeman AT, et al
    Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
    Lung Cancer. 2019;133:110-116.
    PubMed     Text format     Abstract available


  56. GAYE E, Geier M, Bore P, Guilloique M, et al
    Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
    Lung Cancer. 2019;133:1-3.
    PubMed     Text format     Abstract available


    June 2019
  57. PARDO-CABELLO AJ, Manzano-Gamero V
    Small cell lung cancer elevates procalcitonin levels in the absence of infection.
    Lung Cancer. 2019 Jun 17. pii: S0169-5002(19)30511.
    PubMed     Text format    


  58. FUJIMOTO D, Yomota M, Sekine A, Morita M, et al
    Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
    Lung Cancer. 2019 Jun 3. pii: S0169-5002(19)30494.
    PubMed     Text format     Abstract available


  59. YOO JK, Lee JM, Kang SH, Jeon SH, et al
    The novel microRNA hsa-miR-CHA1 regulates cell proliferation and apoptosis in human lung cancer by targeting XIAP.
    Lung Cancer. 2019;132:99-106.
    PubMed     Text format     Abstract available


  60. SUH CH, Kim KW, Pyo J, Hatabu H, et al
    The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis.
    Lung Cancer. 2019;132:79-86.
    PubMed     Text format     Abstract available


  61. GALLI G, Triulzi T, Proto C, Signorelli D, et al
    Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
    Lung Cancer. 2019;132:72-78.
    PubMed     Text format     Abstract available


  62. ASSOUN S, Theou-Anton N, Nguenang M, Cazes A, et al
    Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;132:65-71.
    PubMed     Text format     Abstract available


  63. ICHIHARA E, Hotta K, Ninomiya K, Kubo T, et al
    Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
    Lung Cancer. 2019;132:54-58.
    PubMed     Text format     Abstract available


  64. CUI S, Ni Y, Zhao Y, Li Z, et al
    Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Lung Cancer. 2019;132:45-53.
    PubMed     Text format     Abstract available


  65. WANG H, Agulnik J, Kasymjanova G, Fiset PO, et al
    The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
    Lung Cancer. 2019;132:36-38.
    PubMed     Text format     Abstract available


  66. PLATANIA M, Pasini F, Porcu L, Boeri M, et al
    Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
    Lung Cancer. 2019;132:17-23.
    PubMed     Text format     Abstract available


  67. VAD-NIELSEN J, Gammelgaard KR, Daugaard TF, Nielsen AL, et al
    Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
    Lung Cancer. 2019;132:132-140.
    PubMed     Text format     Abstract available


  68. PARK K, Bennouna J, Boyer M, Hida T, et al
    Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
    Lung Cancer. 2019;132:126-131.
    PubMed     Text format     Abstract available


  69. MINNITI G, Scaringi C, Lanzetta G, Anzellini D, et al
    Comparative effectiveness of multi-fraction stereotactic radiosurgery for surgically resected or intact large brain metastases from non-small-cell lung cancer (NSCLC).
    Lung Cancer. 2019;132:119-125.
    PubMed     Text format     Abstract available


  70. LIANG F, Wu C, Gu H, Zhu M, et al
    Lung cancer incidence in female rises significantly in urban sprawl of Shanghai after introduction of LDCT screening.
    Lung Cancer. 2019;132:114-118.
    PubMed     Text format     Abstract available


  71. OYANAGI J, Koh Y, Sato K, Mori K, et al
    Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Lung Cancer. 2019;132:107-113.
    PubMed     Text format     Abstract available


  72. FUKUDA M, Kitazaki T, Ogawara D, Ichiki M, et al
    Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
    Lung Cancer. 2019;132:1-8.
    PubMed     Text format     Abstract available


    May 2019
  73. TAKANO N, Ariyasu R, Koyama J, Sonoda T, et al
    Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.
    Lung Cancer. 2019;131:69-77.
    PubMed     Text format     Abstract available


  74. LIN C, Shi X, Yang S, Zhao J, et al
    Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;131:62-68.
    PubMed     Text format     Abstract available


  75. PEROL M, Winfree KB, Cuyun Carter G, Lin Cui Z, et al
    Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;131:6-13.
    PubMed     Text format     Abstract available


  76. SULLIVAN DR, Eden KB, Dieckmann NF, Golden SE, et al
    Understanding patients' values and preferences regarding early stage lung cancer treatment decision making.
    Lung Cancer. 2019;131:47-57.
    PubMed     Text format     Abstract available


  77. WILLEN L, Berglund A, Bergstrom S, Bergqvist M, et al
    Educational level and management and outcomes in non-small cell lung cancer. A nationwide population-based study.
    Lung Cancer. 2019;131:40-46.
    PubMed     Text format     Abstract available


  78. VAYR F, Savall F, Bigay-Game L, Soulat JM, et al
    Lung cancer survivors and employment: A systematic review.
    Lung Cancer. 2019;131:31-39.
    PubMed     Text format     Abstract available


  79. MAISONNEUVE P, Rampinelli C, Bertolotti R, Misotti A, et al
    Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos.
    Lung Cancer. 2019;131:23-30.
    PubMed     Text format     Abstract available


  80. YAN SX, Qureshi MM, Dyer M, Truong MT, et al
    Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
    Lung Cancer. 2019;131:147-153.
    PubMed     Text format     Abstract available


  81. YIN K, Li YS, Zheng MM, Jiang BY, et al
    A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
    Lung Cancer. 2019;131:134-138.
    PubMed     Text format     Abstract available


  82. LATTUCA-TRUC M, Timsit JF, Levra MG, Ruckly S, et al
    Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017.
    Lung Cancer. 2019;131:122-127.
    PubMed     Text format     Abstract available


  83. YAMADA T, Ohta K, Motooka Y, Fujino K, et al
    Significance of Tsukushi in lung cancer.
    Lung Cancer. 2019;131:104-111.
    PubMed     Text format     Abstract available


  84. CHRISTENSEN NL, Dalton S, Ravn J, Christensen J, et al
    Treatment, no treatment and early death in Danish stage I lung cancer patients.
    Lung Cancer. 2019;131:1-5.
    PubMed     Text format     Abstract available


    April 2019
  85. LAN S, Li H, Liu Y, Ma L, et al
    Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer.
    Lung Cancer. 2019 Apr 28. pii: S0169-5002(19)30426.
    PubMed     Text format    


  86. FOSTER CC, Rusthoven CG, Sher DJ, Feldman L, et al
    Corrigendum to "Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall survival: A National Cancer Database Analysis" [Lung Cancer, Volume 130 (April) (2019) 162-168].
    Lung Cancer. 2019 Apr 25. pii: S0169-5002(19)30398.
    PubMed     Text format    


  87. NISHIO M, Nakagawa K, Mitsudomi T, Yamamoto N, et al
    Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40].
    Lung Cancer. 2019 Apr 24. pii: S0169-5002(19)30399.
    PubMed     Text format    


  88. WATANABE S, Yoshioka H, Sakai H, Hotta K, et al
    Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lu
    Lung Cancer. 2019 Apr 20. pii: S0169-5002(19)30397.
    PubMed     Text format    


  89. HARRIS EJA, Musk AW, DeKlerk N, Brims FJH, et al
    Correspondence regarding "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
    Lung Cancer. 2019 Apr 20. pii: S0169-5002(19)30417.
    PubMed     Text format    


  90. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes.
    Lung Cancer. 2019;130:93-100.
    PubMed     Text format     Abstract available


  91. LEE K, Kim Y, Jung HA, Lee SH, et al
    Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
    Lung Cancer. 2019;130:87-92.
    PubMed     Text format     Abstract available


  92. JIANG T, Bai Y, Zhou F, Li W, et al
    Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Lung Cancer. 2019;130:76-83.
    PubMed     Text format     Abstract available


  93. ARRIETA O, Barron F, Maldonado F, Cabrera L, et al
    Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
    Lung Cancer. 2019;130:67-75.
    PubMed     Text format     Abstract available


  94. GUBENS MA, Sequist LV, Stevenson JP, Powell SF, et al
    Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
    Lung Cancer. 2019;130:59-66.
    PubMed     Text format     Abstract available


  95. LA FLEUR L, Falk-Sorqvist E, Smeds P, Berglund A, et al
    Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    Lung Cancer. 2019;130:50-58.
    PubMed     Text format     Abstract available


  96. YONESHIMA Y, Tanaka K, Shiraishi Y, Hata K, et al
    Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.
    Lung Cancer. 2019;130:5-9.
    PubMed     Text format     Abstract available


  97. PERUMAL E, So Youn K, Sun S, Seung-Hyun J, et al
    PTEN inactivation induces epithelial-mesenchymal transition and metastasis by intranuclear translocation of beta-catenin and snail/slug in non-small cell lung carcinoma cells.
    Lung Cancer. 2019;130:25-34.
    PubMed     Text format     Abstract available


  98. STEFFENS CC, Elender C, Hutzschenreuter U, Dille S, et al
    Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
    Lung Cancer. 2019;130:216-225.
    PubMed     Text format     Abstract available


  99. LUO Q, Steinberg J, O'Connell DL, Yu XQ, et al
    Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?
    Lung Cancer. 2019;130:208-215.
    PubMed     Text format     Abstract available


  100. WU YL, Zhou C, Lu S, Qin S, et al
    Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
    Lung Cancer. 2019;130:18-24.
    PubMed     Text format     Abstract available


  101. CARNEIRO-LOBO TC, Scalabrini LC, Magalhaes LDS, Cardeal LB, et al
    IKKbeta targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Lung Cancer. 2019;130:169-178.
    PubMed     Text format     Abstract available


  102. FOSTER CC, Rusthoven CG, Sher DJ, Feldman L, et al
    Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
    Lung Cancer. 2019;130:162-168.
    PubMed     Text format     Abstract available


  103. SAKATA Y, Kawamura K, Ichikado K, Shingu N, et al
    The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
    Lung Cancer. 2019;130:159-161.
    PubMed     Text format     Abstract available


  104. BRONSERUD MM, Iachina M, Green A, Groenvold M, et al
    Patient reported outcome data as performance indicators in surgically treated lung cancer patients.
    Lung Cancer. 2019;130:143-148.
    PubMed     Text format     Abstract available


  105. COSTANTINI A, Fallet V, Corny J, Friard S, et al
    Nivolumab-refractory patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2019;130:128-134.
    PubMed     Text format     Abstract available


  106. MELTZER LR, Unrod M, Simmons VN, Brandon KO, et al
    Capitalizing on a teachable moment: Development of a targeted self-help smoking cessation intervention for patients receiving lung cancer screening.
    Lung Cancer. 2019;130:121-127.
    PubMed     Text format     Abstract available


  107. GEERSE OP, Brandenbarg D, Kerstjens HAM, Berendsen AJ, et al
    The distress thermometer as a prognostic tool for one-year survival among patients with lung cancer.
    Lung Cancer. 2019;130:101-107.
    PubMed     Text format     Abstract available


  108. ZHAO S, Gao G, Li W, Li X, et al
    Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
    Lung Cancer. 2019;130:10-17.
    PubMed     Text format     Abstract available


  109. ZHOU K, Zhou J, Huang J, Zhang N, et al
    Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
    Lung Cancer. 2019;130:1-4.
    PubMed     Text format     Abstract available


    March 2019
  110. HU SY, Hsieh MS, Hsu HH, Tsai TM, et al
    Corrigendum to "Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas" [Lung Cancer 126 (2018) 189-193].
    Lung Cancer. 2019 Mar 13. pii: S0169-5002(19)30349.
    PubMed     Text format    


  111. ONO A, Isaka M, Serizawa M, Omae K, et al
    Corrigendum to "Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer" [Lung Cancer 128 (2019) 152-157].
    Lung Cancer. 2019 Mar 12. pii: S0169-5002(19)30350.
    PubMed     Text format    


  112. BRAVACCINI S
    What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
    Lung Cancer. 2019 Mar 11. pii: S0169-5002(19)30355.
    PubMed     Text format     Abstract available


  113. UBERALL I, Gachechiladze M, Joerger M, Andel J, et al
    Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer.
    Lung Cancer. 2019;129:85-91.
    PubMed     Text format     Abstract available


  114. MENDOZA DP, Dagogo-Jack I, Chen T, Padole A, et al
    Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class.
    Lung Cancer. 2019;129:80-84.
    PubMed     Text format     Abstract available


  115. HEILBRONER SP, Xanthopoulos EP, Buono D, Huang Y, et al
    Impact of estrogen monotherapy on survival in women with stage III-IV non-small cell lung cancer.
    Lung Cancer. 2019;129:8-15.
    PubMed     Text format     Abstract available


  116. TUNALI I, Gray JE, Qi J, Abdalah M, et al
    Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
    Lung Cancer. 2019;129:75-79.
    PubMed     Text format     Abstract available


  117. ZHENG X, Zhang G, Li P, Zhang M, et al
    Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.
    Lung Cancer. 2019;129:72-74.
    PubMed     Text format     Abstract available


  118. ANDRATSCHKE N, Kraft J, Nieder C, Tay R, et al
    Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC).
    Lung Cancer. 2019;129:63-71.
    PubMed     Text format     Abstract available


  119. WATANABE S, Yoshioka H, Sakai H, Hotta K, et al
    Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.
    Lung Cancer. 2019;129:55-62.
    PubMed     Text format     Abstract available


  120. KOH YW, Lee SJ, Han JH, Haam S, et al
    PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
    Lung Cancer. 2019;129:41-47.
    PubMed     Text format     Abstract available


  121. CRINO L, Bronte G, Bidoli P, Cravero P, et al
    Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2019;129:35-40.
    PubMed     Text format     Abstract available


  122. GEMINE RE, Ghosal R, Collier G, Parry D, et al
    Longitudinal study to assess impact of smoking at diagnosis and quitting on 1-year survival for people with non-small cell lung cancer.
    Lung Cancer. 2019;129:1-7.
    PubMed     Text format     Abstract available


    February 2019
  123. SHI JF, Wang L, Wu N, Li JL, et al
    Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey.
    Lung Cancer. 2019;128:91-100.
    PubMed     Text format     Abstract available


  124. HORN L, Bauml J, Forde PM, Davis KL, et al
    Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
    Lung Cancer. 2019;128:74-90.
    PubMed     Text format     Abstract available


  125. BRONSERUD MM, Iachina M, Green A, Groenvold M, et al
    Patient-reported outcomes (PROs) in lung cancer: Experiences from a nationwide feasibility study.
    Lung Cancer. 2019;128:67-73.
    PubMed     Text format     Abstract available


  126. YAN X, Wang H, Li P, Zhang G, et al
    Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Lung Cancer. 2019;128:6-12.
    PubMed     Text format     Abstract available


  127. NIEUWENHUIS L, van den Brandt PA
    Nut and peanut butter consumption and the risk of lung cancer and its subtypes: A prospective cohort study.
    Lung Cancer. 2019;128:57-66.
    PubMed     Text format     Abstract available


  128. HAMADA K, Irie M, Fujino Y, Hyodo M, et al
    Prognostic value of preoperative exercise capacity in patients undergoing thoracoscopic lobectomy for non-small cell lung cancer.
    Lung Cancer. 2019;128:47-52.
    PubMed     Text format     Abstract available


  129. ZAMARRON E, Prats E, Tejero E, Pardo P, et al
    Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease.
    Lung Cancer. 2019;128:40-46.
    PubMed     Text format     Abstract available


  130. MIZUGAKI H, Hamada A, Shibata T, Hosoda F, et al
    Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
    Lung Cancer. 2019;128:20-25.
    PubMed     Text format     Abstract available


  131. SCHUCHERT MJ, Normolle DP, Awais O, Pennathur A, et al
    Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer.
    Lung Cancer. 2019;128:145-151.
    PubMed     Text format     Abstract available


  132. CEDILLO JL, Bordas A, Arnalich F, Esteban-Rodriguez I, et al
    Anti-tumoral activity of the human-specific duplicated form of alpha7-nicotinic receptor subunit in tobacco-induced lung cancer progression.
    Lung Cancer. 2019;128:134-144.
    PubMed     Text format     Abstract available


  133. ABEL S, Hasan S, White R, Schumacher L, et al
    Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
    Lung Cancer. 2019;128:127-133.
    PubMed     Text format     Abstract available


  134. KOO HJ, Choi CM, Park S, Lee HN, et al
    Chest radiography surveillance for lung cancer: Results from a National Health Insurance database in South Korea.
    Lung Cancer. 2019;128:120-126.
    PubMed     Text format     Abstract available


  135. ITO K, Miura S, Sakaguchi T, Murotani K, et al
    The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Lung Cancer. 2019;128:113-119.
    PubMed     Text format     Abstract available


  136. GADGEEL SM, Lukas RV, Goldschmidt J, Conkling P, et al
    Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
    Lung Cancer. 2019;128:105-112.
    PubMed     Text format     Abstract available


  137. STEVENS C, Smith SG, Quaife SL, Vrinten C, et al
    Interest in lifestyle advice at lung cancer screening: Determinants and preferences.
    Lung Cancer. 2019;128:1-5.
    PubMed     Text format     Abstract available


    January 2019
  138. HENDRIKS LEL, Dingemans AC
    Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?
    Lung Cancer. 2019 Jan 30. pii: S0169-5002(19)30297.
    PubMed     Text format    


  139. AULIAC JB, Perol M, Planchard D, Monnet I, et al
    Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Lung Cancer. 2019;127:96-102.
    PubMed     Text format     Abstract available


  140. YOON HS, Wen W, Long J, Zheng W, et al
    Association of oral health with lung cancer risk in a low-income population of African Americans and European Americans in the Southeastern United States.
    Lung Cancer. 2019;127:90-95.
    PubMed     Text format     Abstract available


  141. GU X, Zhang Q, Chu YB, Zhao YY, et al
    Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lung Cancer. 2019;127:84-89.
    PubMed     Text format     Abstract available


  142. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer.
    Lung Cancer. 2019;127:76-83.
    PubMed     Text format     Abstract available


  143. DOTSON T, Bellinger C, Su J, Hansen K, et al
    Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial).
    Lung Cancer. 2019;127:6-11.
    PubMed     Text format     Abstract available


  144. SAKAI H, Takeda M, Sakai K, Nakamura Y, et al
    Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Lung Cancer. 2019;127:59-65.
    PubMed     Text format     Abstract available


  145. COUTINHO AD, Shah M, Lunacsek OE, Eaddy M, et al
    Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy.
    Lung Cancer. 2019;127:53-58.
    PubMed     Text format     Abstract available


  146. CHOUAID C, Bensimon L, Clay E, Millier A, et al
    Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Lung Cancer. 2019;127:44-52.
    PubMed     Text format     Abstract available


  147. THOMPSON JC, Fan R, Black T, Yu GH, et al
    Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
    Lung Cancer. 2019;127:25-33.
    PubMed     Text format     Abstract available


  148. YU Y, Ou Q, Wu X, Bao H, et al
    Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2019;127:19-24.
    PubMed     Text format     Abstract available


  149. HASEGAWA H, Yasuda H, Hamamoto J, Masuzawa K, et al
    Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
    Lung Cancer. 2019;127:146-152.
    PubMed     Text format     Abstract available


  150. MONSALVE AF, Hoag JR, Resio BJ, Chiu AS, et al
    Variable impact of prior cancer history on the survival of lung cancer patients.
    Lung Cancer. 2019;127:130-137.
    PubMed     Text format     Abstract available


  151. MURAWSKI M, Walter J, Schwarzkopf L
    Assessing the lung cancer comorbidome: An analysis of German claims data.
    Lung Cancer. 2019;127:122-129.
    PubMed     Text format     Abstract available


  152. PYO KH, Kim JH, Lee JM, Kim SE, et al
    Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
    Lung Cancer. 2019;127:112-121.
    PubMed     Text format     Abstract available


  153. WU YL, Zhao Q, Deng L, Zhang Y, et al
    Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
    Lung Cancer. 2019;127:1-5.
    PubMed     Text format     Abstract available


  154. SUH CH, Kim KW, Nishino M
    Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis i
    Lung Cancer. 2019;127:168.
    PubMed     Text format    


    December 2018
  155. LIN YT, Chu CY
    Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer.
    Lung Cancer. 2018 Dec 31. pii: S0169-5002(18)30730.
    PubMed     Text format    


  156. ONO A, Isaka M, Serizawa M, Omae K, et al
    Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer.
    Lung Cancer. 2018 Dec 5. pii: S0169-5002(18)30691.
    PubMed     Text format     Abstract available


  157. CAPIZZI E, Ricci C, Giunchi F, Zagnoni S, et al
    Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
    Lung Cancer. 2018;126:9-14.
    PubMed     Text format     Abstract available


  158. UNG MH, MacKenzie TA, Onega TL, Amos CI, et al
    Statins associate with improved mortality among patients with certain histological subtypes of lung cancer.
    Lung Cancer. 2018;126:89-96.
    PubMed     Text format     Abstract available


  159. KOGA T, Kobayashi Y, Tomizawa K, Suda K, et al
    Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
    Lung Cancer. 2018;126:72-79.
    PubMed     Text format     Abstract available


  160. MOREL H, Raynard B, d'Arlhac M, Hauss PA, et al
    Prediagnosis weight loss, a stronger factor than BMI, to predict survival in patients with lung cancer.
    Lung Cancer. 2018;126:55-63.
    PubMed     Text format     Abstract available


  161. HASHEMI SADRAEI N, Feng Y, Du L, Fu P, et al
    High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
    Lung Cancer. 2018;126:48-54.
    PubMed     Text format     Abstract available


  162. IMAI H, Kaira K, Suzuki K, Anzai M, et al
    A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
    Lung Cancer. 2018;126:41-47.
    PubMed     Text format     Abstract available


  163. MEIJER TWH, Peeters WJM, Dubois LJ, van Gisbergen MW, et al
    Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer.
    Lung Cancer. 2018;126:32-40.
    PubMed     Text format     Abstract available


  164. UDAGAWA H, Umemura S, Murakami I, Mimaki S, et al
    Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
    Lung Cancer. 2018;126:182-188.
    PubMed     Text format     Abstract available


  165. SCHWYZER M, Ferraro DA, Muehlematter UJ, Curioni-Fontecedro A, et al
    Automated detection of lung cancer at ultralow dose PET/CT by deep neural networks - Initial results.
    Lung Cancer. 2018;126:170-173.
    PubMed     Text format     Abstract available


  166. ANAI S, Iwama E, Yoneshima Y, Otsubo K, et al
    Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
    Lung Cancer. 2018;126:156-161.
    PubMed     Text format     Abstract available


  167. JOHN T, Akamatsu H, Delmonte A, Su WC, et al
    EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
    Lung Cancer. 2018;126:133-138.
    PubMed     Text format     Abstract available


  168. QUIST M, Sommer MS, Vibe-Petersen J, Staerkind MB, et al
    Early initiated postoperative rehabilitation reduces fatigue in patients with operable lung cancer: A randomized trial.
    Lung Cancer. 2018;126:125-132.
    PubMed     Text format     Abstract available


  169. HINDE S, Crilly T, Balata H, Bartlett R, et al
    The cost-effectiveness of the Manchester 'lung health checks', a community-based lung cancer low-dose CT screening pilot.
    Lung Cancer. 2018;126:119-124.
    PubMed     Text format     Abstract available


  170. NG TL, Morgan RL, Patil T, Baron AE, et al
    Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.
    Lung Cancer. 2018;126:112-118.
    PubMed     Text format     Abstract available


    November 2018
  171. SATO K, Akamatsu H, Murakami E, Sasaki S, et al
    Corrigendum to "Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab" [Lung Cancer 115 (2018) 71-74].
    Lung Cancer. 2018 Nov 17. pii: S0169-5002(18)30635.
    PubMed     Text format    


  172. TANAKA I, Morise M, Kodama Y, Matsui A, et al
    Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.
    Lung Cancer. 2018 Nov 14. pii: S0169-5002(18)30645.
    PubMed     Text format    


  173. SUN Z, Sui X, Yang F, Wang J, et al
    Effects of primary tumor resection on the survival of patients with stage IV extrathoracic metastatic non-small cell lung cancer: A population-based study.
    Lung Cancer. 2018 Nov 13. pii: S0169-5002(18)30639.
    PubMed     Text format     Abstract available


  174. ZHAO B, Zhang W
    Reply to the comments on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Lung Cancer. 2018 Nov 12. pii: S0169-5002(18)30638.
    PubMed     Text format    


  175. HANIBUCHI M, Kakiuchi S, Atagi S, Ogushi F, et al
    A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
    Lung Cancer. 2018;125:93-99.
    PubMed     Text format     Abstract available


  176. LIU SY, Dong ZY, Wu SP, Xie Z, et al
    Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Lung Cancer. 2018;125:86-92.
    PubMed     Text format     Abstract available


  177. CHEN K, Yu X, Zhang F, Xu Y, et al
    Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases.
    Lung Cancer. 2018;125:8-13.
    PubMed     Text format     Abstract available


  178. COSTA GJ, de Mello MJG, Ferreira CG, Bergmann A, et al
    Increased incidence, morbidity and mortality rates for lung cancer in women in Brazil between 2000 and 2014: An analysis of three types of sources of secondary data.
    Lung Cancer. 2018;125:77-85.
    PubMed     Text format     Abstract available


  179. LUO Q, Yu XQ, Wade S, Caruana M, et al
    Lung cancer mortality in Australia: Projected outcomes to 2040.
    Lung Cancer. 2018;125:68-76.
    PubMed     Text format     Abstract available


  180. CHECK DK, Albers KB, Uppal KM, Suga JM, et al
    Examining the role of access to care: Racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members.
    Lung Cancer. 2018;125:51-56.
    PubMed     Text format     Abstract available


  181. SOTIROPOULOS GP, Dalamaga M, Antonakos G, Marinou I, et al
    Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.
    Lung Cancer. 2018;125:291-299.
    PubMed     Text format     Abstract available


  182. BALATA H, Foden P, Edwards T, Chaturvedi A, et al
    Predicting survival following surgical resection of lung cancer using clinical and pathological variables: The development and validation of the LNC-PATH score.
    Lung Cancer. 2018;125:29-34.
    PubMed     Text format     Abstract available


  183. LIN MW, Su KY, Su TJ, Chang CC, et al
    Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lung Cancer. 2018;125:282-290.
    PubMed     Text format     Abstract available


  184. GADGEEL SM, Stevenson JP, Langer CJ, Gandhi L, et al
    Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
    Lung Cancer. 2018;125:273-281.
    PubMed     Text format     Abstract available


  185. ISOBE K, Kaburaki K, Kobayashi H, Sano G, et al
    New risk scoring system for predicting acute exacerbation of interstitial pneumonia after chemotherapy for lung cancer associated with interstitial pneumonia.
    Lung Cancer. 2018;125:253-257.
    PubMed     Text format     Abstract available


  186. WANG S, Zhang B, Qian J, Qiao R, et al
    Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.
    Lung Cancer. 2018;125:245-252.
    PubMed     Text format     Abstract available


  187. JEGOU D, Dubois C, Schillemans V, Stordeur S, et al
    Use of health insurance data to identify and quantify the prevalence of main comorbidities in lung cancer patients.
    Lung Cancer. 2018;125:238-244.
    PubMed     Text format     Abstract available


  188. SAITO T, Tsuta K, Ishida M, Ryota H, et al
    Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients.
    Lung Cancer. 2018;125:230-237.
    PubMed     Text format     Abstract available


  189. KORT S, Tiggeloven MM, Brusse-Keizer M, Gerritsen JW, et al
    Multi-centre prospective study on diagnosing subtypes of lung cancer by exhaled-breath analysis.
    Lung Cancer. 2018;125:223-229.
    PubMed     Text format     Abstract available


  190. JIA Y, Li X, Zhao C, Jiang T, et al
    Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;125:22-28.
    PubMed     Text format     Abstract available


  191. YAMAGUCHI T, Shimizu J, Hasegawa T, Horio Y, et al
    Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
    Lung Cancer. 2018;125:212-217.
    PubMed     Text format     Abstract available


  192. MALHOTRA J, Rotter D, Jabbour SK, Aisner J, et al
    Receipt of recommended surveillance with imaging in elderly survivors of early stage non-small cell lung cancer.
    Lung Cancer. 2018;125:205-211.
    PubMed     Text format     Abstract available


  193. YUTAKA Y, Sonobe M, Kawaguchi A, Hamaji M, et al
    Prognostic impact of preoperative comorbidities in geriatric patients with early-stage lung cancer: Significance of sublobar resection as a compromise procedure.
    Lung Cancer. 2018;125:192-197.
    PubMed     Text format     Abstract available


  194. KARLSSON T, Kvarnbrink S, Holmlund C, Botling J, et al
    LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.
    Lung Cancer. 2018;125:174-184.
    PubMed     Text format     Abstract available


  195. FROST N, Tessmer A, Schmittel A, van Laak V, et al
    Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
    Lung Cancer. 2018;125:164-173.
    PubMed     Text format     Abstract available


  196. DJUREINOVIC D, Dodig-Crnkovic T, Hellstrom C, Holgersson G, et al
    Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer.
    Lung Cancer. 2018;125:157-163.
    PubMed     Text format     Abstract available


  197. CHO JY, Kim J, Lee JS, Kim YJ, et al
    Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Lung Cancer. 2018;125:150-156.
    PubMed     Text format     Abstract available


  198. KAWANO Y, Sasaki T, Yamaguchi H, Hirano K, et al
    Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2018;125:136-141.
    PubMed     Text format     Abstract available


  199. DEJIMA H, Nakanishi H, Kuroda H, Yoshimura M, et al
    Detection of abundant megakaryocytes in pulmonary artery blood in lung cancer patients using a microfluidic platform.
    Lung Cancer. 2018;125:128-135.
    PubMed     Text format     Abstract available


  200. MOFFAT J, Hiom S, Kumar HS, Baldwin DR, et al
    Lung cancer screening - gaining consensus on next steps - proceedings of a closed workshop in the UK.
    Lung Cancer. 2018;125:121-127.
    PubMed     Text format     Abstract available


  201. REN S, Tian Q, Amar N, Yu H, et al
    The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
    Lung Cancer. 2018;125:115-120.
    PubMed     Text format     Abstract available


  202. WALTER JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, et al
    Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study.
    Lung Cancer. 2018;125:103-108.
    PubMed     Text format     Abstract available


  203. EZEIFE DA, Kirk V, Chew DS, Nixon NA, et al
    Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
    Lung Cancer. 2018;125:1-7.
    PubMed     Text format     Abstract available


    October 2018
  204. LUCCHESI C, Drogat B, Santamaria D, Cousin S, et al
    Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer.
    Lung Cancer. 2018 Oct 12. pii: S0169-5002(18)30597.
    PubMed     Text format    


  205. ILIE M, Beaulande M, Hamila M, Erb G, et al
    Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.
    Lung Cancer. 2018;124:90-94.
    PubMed     Text format     Abstract available


  206. HARRIS JP, Nwachukwu C, Qian Y, Pollom E, et al
    Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer.
    Lung Cancer. 2018;124:76-85.
    PubMed     Text format     Abstract available


  207. UCHIBORI K, Satouchi M, Sueoka-Aragane N, Urata Y, et al
    Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
    Lung Cancer. 2018;124:65-70.
    PubMed     Text format     Abstract available


  208. DE JONG EEC, van Elmpt W, Rizzo S, Colarieti A, et al
    Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.
    Lung Cancer. 2018;124:6-11.
    PubMed     Text format     Abstract available


  209. FERRER I, Zugazagoitia J, Herbertz S, John W, et al
    KRAS-Mutant non-small cell lung cancer: From biology to therapy.
    Lung Cancer. 2018;124:53-64.
    PubMed     Text format     Abstract available


  210. CHRISTENSEN NL, Lokke A, Dalton SO, Christensen J, et al
    Smoking, alcohol, and nutritional status in relation to one-year mortality in Danish stage I lung cancer patients.
    Lung Cancer. 2018;124:40-44.
    PubMed     Text format     Abstract available


  211. BIRCAN HA, Gurbuz N, Pataer A, Caner A, et al
    Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
    Lung Cancer. 2018;124:31-39.
    PubMed     Text format     Abstract available


  212. LIM SW, Park S, Kim Y, Cho JH, et al
    Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.
    Lung Cancer. 2018;124:293-297.
    PubMed     Text format     Abstract available


  213. HASAN S, Renz P, Turrisi A, Colonias A, et al
    Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis.
    Lung Cancer. 2018;124:283-290.
    PubMed     Text format     Abstract available


  214. MESSARITAKIS I, Nikolaou M, Politaki E, Koinis F, et al
    Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment.
    Lung Cancer. 2018;124:270-278.
    PubMed     Text format     Abstract available


  215. OKAMOTO T, Yano T, Shimokawa M, Takeo S, et al
    A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
    Lung Cancer. 2018;124:255-259.
    PubMed     Text format     Abstract available


  216. GEORGIEVA M, da Silveira Nogueira Lima JP, Aguiar P Jr, de Lima Lopes G Jr, et al
    Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
    Lung Cancer. 2018;124:248-254.
    PubMed     Text format     Abstract available


  217. HASHIMOTO T, Osoegawa A, Takumi Y, Abe M, et al
    Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining.
    Lung Cancer. 2018;124:241-247.
    PubMed     Text format     Abstract available


  218. JAINE R, Kvizhinadze G, Nair N, Blakely T, et al
    Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
    Lung Cancer. 2018;124:233-240.
    PubMed     Text format     Abstract available


  219. NAJJAR F, Alammar M, Al-Massarani G, Almalla N, et al
    Circulating endothelial cells and microparticles as diagnostic and prognostic biomarkers in small-cell lung cancer.
    Lung Cancer. 2018;124:23-30.
    PubMed     Text format     Abstract available


  220. HSIEH MS, Lee YH, Lin MW, Chen JS, et al
    Solitary pulmonary capillary hemangioma: An under-recognized pulmonary lesion mimicking early lung cancer on computed tomography images.
    Lung Cancer. 2018;124:227-232.
    PubMed     Text format     Abstract available


  221. MERINO LARA T, Helou J, Poon I, Sahgal A, et al
    Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
    Lung Cancer. 2018;124:219-226.
    PubMed     Text format     Abstract available


  222. STONE E, Rankin N, Kerr S, Fong K, et al
    Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study.
    Lung Cancer. 2018;124:199-204.
    PubMed     Text format     Abstract available


  223. HOFER F, Kauczor HU, Stargardt T
    Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach.
    Lung Cancer. 2018;124:189-198.
    PubMed     Text format     Abstract available


  224. SEKINE K, Kanda S, Goto Y, Horinouchi H, et al
    Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
    Lung Cancer. 2018;124:179-188.
    PubMed     Text format     Abstract available


  225. KANG HN, Choi JW, Shim HS, Kim J, et al
    Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    Lung Cancer. 2018;124:168-178.
    PubMed     Text format     Abstract available


  226. CLARK ME, Bedford LE, Young B, Robertson JFR, et al
    Lung cancer CT screening: Psychological responses in the presence and absence of pulmonary nodules.
    Lung Cancer. 2018;124:160-167.
    PubMed     Text format     Abstract available


  227. SIM WC, Loh CH, Toh GL, Lim CW, et al
    Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Lung Cancer. 2018;124:154-159.
    PubMed     Text format     Abstract available


  228. BALATA H, Blandin Knight S, Barber P, Colligan D, et al
    Targeted lung cancer screening selects individuals at high risk of cardiovascular disease.
    Lung Cancer. 2018;124:148-153.
    PubMed     Text format     Abstract available


  229. LAFITTE C, Etienne-Mastroianni B, Fournel C, Natoli L, et al
    Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancer.
    Lung Cancer. 2018;124:143-147.
    PubMed     Text format     Abstract available


  230. YAN SX, Qureshi MM, Suzuki K, Dyer M, et al
    Definitive treatment patterns and survival in stage II non-small cell lung cancer.
    Lung Cancer. 2018;124:135-142.
    PubMed     Text format     Abstract available


  231. DUDNIK E, Bshara E, Grubstein A, Fridel L, et al
    Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
    Lung Cancer. 2018;124:117-124.
    PubMed     Text format     Abstract available


  232. GRANGER CL, Irving L, Antippa P, Edbrooke L, et al
    CAPACITY: A physical activity self-management program for patients undergoing surgery for lung cancer, a phase I feasibility study.
    Lung Cancer. 2018;124:102-109.
    PubMed     Text format     Abstract available


  233. MATYS T, Drury R, David S, Rassl DM, et al
    Corrigendum to "Routine preoperative brain CT in resectable non-small cell lung cancer-Ten years experience from a tertiary UK thoracic center" [Lung Cancer 122 (August) (2018) 195-199].
    Lung Cancer. 2018 Oct 1. pii: S0169-5002(18)30575.
    PubMed     Text format    


    September 2018
  234. XU R, Zhu J
    Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
    Lung Cancer. 2018 Sep 24. pii: S0169-5002(18)30577.
    PubMed     Text format    


  235. XU R, Zhu J
    Comment on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Lung Cancer. 2018 Sep 7. pii: S0169-5002(18)30559.
    PubMed     Text format    


  236. GARON EB, Siegfried JM, Stabile LP, Young PA, et al
    Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
    Lung Cancer. 2018;123:91-98.
    PubMed     Text format     Abstract available


  237. SCILLA KA, Zandberg DP, Bentzen SM, Mainor C, et al
    Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
    Lung Cancer. 2018;123:87-90.
    PubMed     Text format     Abstract available


  238. VUONG HG, Ho ATN, Altibi AMA, Nakazawa T, et al
    Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
    Lung Cancer. 2018;123:76-82.
    PubMed     Text format     Abstract available


  239. JIAO XD, Qin BD, You P, Cai J, et al
    The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Lung Cancer. 2018;123:70-75.
    PubMed     Text format     Abstract available


  240. SONG Y, Zhou Q, Zhang X, Chen GY, et al
    Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).
    Lung Cancer. 2018;123:7-13.
    PubMed     Text format     Abstract available


  241. SUH CH, Park HS, Kim KW, Pyo J, et al
    Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
    Lung Cancer. 2018;123:60-69.
    PubMed     Text format     Abstract available


  242. LU S, Kong H, Hou Y, Ge D, et al
    Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer.
    Lung Cancer. 2018;123:44-51.
    PubMed     Text format     Abstract available


  243. LIU F, Liu Y, Liu X, Mao K, et al
    Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
    Lung Cancer. 2018;123:36-43.
    PubMed     Text format     Abstract available


  244. TAIRA N, Atsumi E, Nakachi S, Takamatsu R, et al
    Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the (18)F-FDG PET/CT mediastinal nodal staging of non-small cell lung cancer.
    Lung Cancer. 2018;123:30-35.
    PubMed     Text format     Abstract available


  245. JAO K, Tomasini P, Kamel-Reid S, Korpanty GJ, et al
    The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Lung Cancer. 2018;123:22-29.
    PubMed     Text format     Abstract available


  246. HU X, Hay JW
    First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
    Lung Cancer. 2018;123:166-171.
    PubMed     Text format     Abstract available


  247. STEWART I, Khakwani A, Hubbard RB, Beckett P, et al
    Are working practices of lung cancer nurse specialists associated with variation in peoples' receipt of anticancer therapy?
    Lung Cancer. 2018;123:160-165.
    PubMed     Text format     Abstract available


  248. CARDINALE D, Cosentino N, Moltrasio M, Sandri MT, et al
    Acute kidney injury after lung cancer surgery: Incidence and clinical relevance, predictors, and role of N-terminal pro B-type natriuretic peptide.
    Lung Cancer. 2018;123:155-159.
    PubMed     Text format     Abstract available


  249. POMPILI C, Koller M, Velikova G, Franks K, et al
    EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC).
    Lung Cancer. 2018;123:149-154.
    PubMed     Text format     Abstract available


  250. CHO BC, Dy GK, Govindan R, Kim DW, et al
    Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
    Lung Cancer. 2018;123:14-21.
    PubMed     Text format     Abstract available


  251. FINKLE JH, Penney BC, Pu Y
    An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
    Lung Cancer. 2018;123:136-141.
    PubMed     Text format     Abstract available


  252. LI Z, Maeda D, Yoshida M, Umakoshi M, et al
    The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
    Lung Cancer. 2018;123:127-135.
    PubMed     Text format     Abstract available


  253. KOUL R, Rathod S, Dubey A, Bashir B, et al
    Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment.
    Lung Cancer. 2018;123:116-120.
    PubMed     Text format     Abstract available


  254. DE JONG EEC, Hendriks LEL, van Elmpt W, Gietema HA, et al
    What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer.
    Lung Cancer. 2018;123:112-115.
    PubMed     Text format     Abstract available


  255. HASHIMOTO K, Daddi N, Giuliani M, Hope A, et al
    The role of endobronchial ultrasound-guided transbronchial needle aspiration in stereotactic body radiation therapy for non-small cell lung cancer.
    Lung Cancer. 2018;123:1-6.
    PubMed     Text format     Abstract available


    August 2018
  256. DICKHOFF C, Dahele M
    In Regard to Robinson et al: Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.
    Lung Cancer. 2018 Aug 16. pii: S0169-5002(18)30527.
    PubMed     Text format    


  257. CHOUAID C, Danson S, Andreas S, Siakpere O, et al
    Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.
    Lung Cancer. 2018 Aug 10. pii: S0169-5002(18)30503.
    PubMed     Text format     Abstract available


  258. LEE YG, Lee JH, Kim SH, Kim YJ, et al
    Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study.
    Lung Cancer. 2018;122:88-93.
    PubMed     Text format     Abstract available


  259. HO JC, Leung CC
    Management of co-existent tuberculosis and lung cancer.
    Lung Cancer. 2018;122:83-87.
    PubMed     Text format     Abstract available


  260. GUIBERT N, Tsukada H, Hwang DH, Chambers E, et al
    Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.
    Lung Cancer. 2018;122:72-75.
    PubMed     Text format     Abstract available


  261. CHAFT JE, Dagogo-Jack I, Santini FC, Eng J, et al
    Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
    Lung Cancer. 2018;122:67-71.
    PubMed     Text format     Abstract available


  262. DENG W, Xu T, Wang Y, Xu Y, et al
    Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer.
    Lung Cancer. 2018;122:60-66.
    PubMed     Text format     Abstract available


  263. OSUOHA CA, Callahan KE, Ponce CP, Pinheiro PS, et al
    Disparities in lung cancer survival and receipt of surgical treatment.
    Lung Cancer. 2018;122:54-59.
    PubMed     Text format     Abstract available


  264. SI X, Zhang L, Wang H, Zhang X, et al
    Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:32-37.
    PubMed     Text format     Abstract available


  265. TRIPHURIDET N, Vidhyarkorn S, Worakitsitisatorn A, Sricharunrat T, et al
    Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
    Lung Cancer. 2018;122:243-248.
    PubMed     Text format     Abstract available


  266. LEE JS, Lee KH, Cho EK, Kim DW, et al
    Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
    Lung Cancer. 2018;122:234-242.
    PubMed     Text format     Abstract available


  267. ZAHEDI A, Phandthong R, Chaili A, Remark G, et al
    Epithelial-to-mesenchymal transition of A549 lung cancer cells exposed to electronic cigarettes.
    Lung Cancer. 2018;122:224-233.
    PubMed     Text format     Abstract available


  268. AHMED T, Vial MR, Ost D, Stewart J, et al
    Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series.
    Lung Cancer. 2018;122:220-223.
    PubMed     Text format     Abstract available


  269. TAKAHASHI N, Tsuji K, Tamiya H, Shinohara T, et al
    Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report.
    Lung Cancer. 2018;122:22-24.
    PubMed     Text format     Abstract available


  270. GOYAL G, Kommalapati A, Bartley AC, Gunderson TM, et al
    Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer.
    Lung Cancer. 2018;122:214-219.
    PubMed     Text format     Abstract available


  271. ROBINSON LA, Tanvetyanon T, Grubbs D, Antonia S, et al
    Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.
    Lung Cancer. 2018;122:206-213.
    PubMed     Text format     Abstract available


  272. IZUMI H, Yamasaki A, Takeda K, Kodani M, et al
    Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:200-205.
    PubMed     Text format     Abstract available


  273. MATYS T, Drury R, David S, Rassl DM, et al
    Routine preoperative brain CT in resectable non-small cell lung cancer - Ten years experience from a tertiary UK thoracic center.
    Lung Cancer. 2018;122:195-199.
    PubMed     Text format     Abstract available


  274. YAP S, Goldsbury D, Yap ML, Yuill S, et al
    Patterns of care and emergency presentations for people with non-small cell lung cancer in New South Wales, Australia: A population-based study.
    Lung Cancer. 2018;122:171-179.
    PubMed     Text format     Abstract available


  275. BRUSTUGUN OT, Gronberg BH, Fjellbirkeland L, Helbekkmo N, et al
    Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016.
    Lung Cancer. 2018;122:138-145.
    PubMed     Text format     Abstract available


  276. MILLARES L, Barreiro E, Cortes R, Martinez-Romero A, et al
    Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance.
    Lung Cancer. 2018;122:124-130.
    PubMed     Text format     Abstract available


  277. INOUE T, Katoh N, Ito YM, Kimura T, et al
    Stereotactic body radiotherapy to treat small lung lesions clinically diagnosed as primary lung cancer by radiological examination: A prospective observational study.
    Lung Cancer. 2018;122:107-112.
    PubMed     Text format     Abstract available


  278. SEBASTIAN M, Ryden A, Walding A, Papadimitrakopoulou V, et al
    Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:100-106.
    PubMed     Text format     Abstract available


  279. ZHAO B, Zhang W, Yu D, Xu J, et al
    Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Lung Cancer. 2018;122:10-21.
    PubMed     Text format     Abstract available


  280. WANG H, Zhang L, Hu P, Zheng X, et al
    Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation.
    Lung Cancer. 2018;122:1-6.
    PubMed     Text format     Abstract available


    July 2018
  281. TENDLER S, Grozman V, Lewensohn R, Tsakonas G, et al
    Corrigendum to "Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden" [Lung Cancer 120 (June) (2018) 75-81].
    Lung Cancer. 2018 Jul 13. pii: S0169-5002(18)30468.
    PubMed     Text format    


  282. VERONESI G, Zulueta JJ, Maisonneuve P, Henschke C, et al
    At last we can go ahead with low-dose CT screening for lung cancer in Europe.
    Lung Cancer. 2018 Jul 10. pii: S0169-5002(18)30470.
    PubMed     Text format    


  283. KUIJPERS CCHJ, Hendriks LEL, Derks JL, Dingemans AC, et al
    Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.
    Lung Cancer. 2018;121:76-81.
    PubMed     Text format     Abstract available


  284. TOMONAGA Y, Ten Haaf K, Frauenfelder T, Kohler M, et al
    Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.
    Lung Cancer. 2018;121:61-69.
    PubMed     Text format     Abstract available


  285. XIE F, Zhang Y, Mao X, Zheng X, et al
    Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naive advanced non-squamous non-small cell lung cancer patients.
    Lung Cancer. 2018;121:54-60.
    PubMed     Text format     Abstract available


  286. NIE K, Zhang Z, Zhang C, Geng C, et al
    Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
    Lung Cancer. 2018;121:5-11.
    PubMed     Text format     Abstract available


  287. KOBAYASHI H, Naito T, Omae K, Omori S, et al
    ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease.
    Lung Cancer. 2018;121:48-53.
    PubMed     Text format     Abstract available


  288. NISHIO M, Nakagawa K, Mitsudomi T, Yamamoto N, et al
    Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2018;121:37-40.
    PubMed     Text format     Abstract available


  289. TOPKAN E, Selek U, Ozdemir Y, Yildirim BA, et al
    Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
    Lung Cancer. 2018;121:30-36.
    PubMed     Text format     Abstract available


  290. YANG M, Tong X, Xu X, Zheng E, et al
    Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex.
    Lung Cancer. 2018;121:1-4.
    PubMed     Text format     Abstract available


    June 2018
  291. ANDREAS S, Chouaid C, Danson S, Siakpere O, et al
    Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
    Lung Cancer. 2018 Jun 9. pii: S0169-5002(18)30416.
    PubMed     Text format     Abstract available


  292. KIMURA S, Harada T, Ijichi K, Tanaka K, et al
    Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer.
    Lung Cancer. 2018;120:98-107.
    PubMed     Text format     Abstract available


  293. LIMWATTANANON C, Limwattananon S, Waleekhachonloet O, Rattanachotphanit T, et al
    Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.
    Lung Cancer. 2018;120:91-97.
    PubMed     Text format     Abstract available


  294. ROBIN TP, Jones BL, Amini A, Koshy M, et al
    Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer.
    Lung Cancer. 2018;120:88-90.
    PubMed     Text format     Abstract available


  295. TENDLER S, Grozman V, Lewensohn R, Tsakonas G, et al
    Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden.
    Lung Cancer. 2018;120:75-81.
    PubMed     Text format     Abstract available


  296. RECK M, Garassino MC, Imbimbo M, Shepherd FA, et al
    Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
    Lung Cancer. 2018;120:62-69.
    PubMed     Text format     Abstract available


  297. LEE CC, Zheng H, Soon YY, Foo LL, et al
    Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy.
    Lung Cancer. 2018;120:54-59.
    PubMed     Text format     Abstract available


  298. FORSTER M, Hackshaw A, De Pas T, Cobo M, et al
    A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
    Lung Cancer. 2018;120:27-33.
    PubMed     Text format     Abstract available


  299. BRADBURY PA, Morris DG, Nicholas G, Tu D, et al
    Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
    Lung Cancer. 2018;120:142-148.
    PubMed     Text format     Abstract available


  300. MAYMANI H, Hess K, Groisberg R, Hong DS, et al
    Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
    Lung Cancer. 2018;120:137-141.
    PubMed     Text format     Abstract available


  301. DU M, Thompson J, Fisher H, Zhang P, et al
    Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Lung Cancer. 2018;120:113-121.
    PubMed     Text format     Abstract available


  302. GUIBERT N, Delaunay M, Lusque A, Boubekeur N, et al
    PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Lung Cancer. 2018;120:108-112.
    PubMed     Text format     Abstract available


  303. REITER MJ, Nemesure A, Madu E, Reagan L, et al
    Frequency and distribution of incidental findings deemed appropriate for S modifier designation on low-dose CT in a lung cancer screening program.
    Lung Cancer. 2018;120:1-6.
    PubMed     Text format     Abstract available


    May 2018
  304. BRAILLON A
    Second-line therapy and advanced non-small cell lung cancer: What about smoking?
    Lung Cancer. 2018 May 21. pii: S0169-5002(18)30382.
    PubMed     Text format    


  305. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
    Lung Cancer. 2018 May 3. pii: S0169-5002(18)30350.
    PubMed     Text format    


  306. D'SILVA A, Gardiner PA, Boyle T, Bebb DG, et al
    Associations of objectively assessed physical activity and sedentary time with health-related quality of life among lung cancer survivors: A quantile regression approach.
    Lung Cancer. 2018;119:78-84.
    PubMed     Text format     Abstract available


  307. RAEZ LE, Cardona AF, Santos ES, Catoe H, et al
    The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments.
    Lung Cancer. 2018;119:7-13.
    PubMed     Text format     Abstract available


  308. YANG SM, Chen LW, Wang HJ, Chen LR, et al
    Extraction of radiomic values from lung adenocarcinoma with near-pure subtypes in the International Association for the Study of Lung Cancer/the American Thoracic Society/the European Respiratory Society (IASLC/ATS/ERS) classification.
    Lung Cancer. 2018;119:56-63.
    PubMed     Text format     Abstract available


  309. CHRISTOPOULOS P, Schneider MA, Bozorgmehr F, Kuon J, et al
    Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance.
    Lung Cancer. 2018;119:48-55.
    PubMed     Text format     Abstract available


  310. MODING EJ, Diehn M, Wakelee HA
    Circulating tumor DNA testing in advanced non-small cell lung cancer.
    Lung Cancer. 2018;119:42-47.
    PubMed     Text format     Abstract available


  311. FUJIMOTO D, Yoshioka H, Kataoka Y, Morimoto T, et al
    Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
    Lung Cancer. 2018;119:14-20.
    PubMed     Text format     Abstract available


  312. BORGHAEI H, Yim YM, Guerin A, Pivneva I, et al
    Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
    Lung Cancer. 2018;119:112-119.
    PubMed     Text format     Abstract available


  313. BURUDPAKDEE C, Wong W, Seetasith A, Corvino FA, et al
    Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2018;119:103-111.
    PubMed     Text format     Abstract available


  314. KANG YK, Song YS, Cho S, Jheon S, et al
    Prognostic stratification model for patients with stage I non-small cell lung cancer adenocarcinoma treated with surgical resection without adjuvant therapies using metabolic features measured on F-18 FDG PET and postoperative pathologic factors.
    Lung Cancer. 2018;119:1-6.
    PubMed     Text format     Abstract available


    April 2018
  315. TSAO MS, Yoon JY
    The eighth TNM classification for lung cancer-What is next?
    Lung Cancer. 2018 Apr 25. pii: S0169-5002(18)30346.
    PubMed     Text format    


  316. YEN CC, Su HC, Chu CY, Lai SJ, et al
    Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy.
    Lung Cancer. 2018 Apr 17. pii: S0169-5002(18)30342.
    PubMed     Text format    


  317. LIAO WY, Ho CC, Tsai TH, Chen KY, et al
    Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Lung Cancer. 2018;118:90-96.
    PubMed     Text format     Abstract available


  318. HAINSWORTH JD, Waterhouse DM, Shih KC, Boccia RV, et al
    Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
    Lung Cancer. 2018;118:6-12.
    PubMed     Text format     Abstract available


  319. SONG Z, Cheng G, Xu C, Wang W, et al
    Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:57-61.
    PubMed     Text format     Abstract available


  320. LEE JW, Choi JS, Lyu J, Lee SM, et al
    Prognostic significance of (18)F-fluorodeoxyglucose uptake of bone marrow measured on positron emission tomography in patients with small cell lung cancer.
    Lung Cancer. 2018;118:41-47.
    PubMed     Text format     Abstract available


  321. BAINE MJ, Verma V, Schonewolf CA, Lin C, et al
    Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Lung Cancer. 2018;118:20-26.
    PubMed     Text format     Abstract available


  322. HELFRICH BA, Gao D, Bunn PA Jr
    Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
    Lung Cancer. 2018;118:148-154.
    PubMed     Text format     Abstract available


  323. HUDSON A, Chan C, Woolf D, McWilliam A, et al
    Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?
    Lung Cancer. 2018;118:139-147.
    PubMed     Text format     Abstract available


  324. SAKAKURA N, Mizuno T, Kuroda H, Arimura T, et al
    The eighth TNM classification system for lung cancer: A consideration based on the degree of pleural invasion and involved neighboring structures.
    Lung Cancer. 2018;118:134-138.
    PubMed     Text format     Abstract available


  325. IMAI S, Kobayashi M, Takasaki C, Ishibashi H, et al
    High expression of P-cadherin is significantly associated with poor prognosis in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:13-19.
    PubMed     Text format     Abstract available


  326. COUNAGO F, Rodriguez de Dios N, Montemuino S, Jove-Teixido J, et al
    Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Lung Cancer. 2018;118:119-127.
    PubMed     Text format     Abstract available


  327. FILIPSKA M, Skrzypski M, Czetyrbok K, Stokowy T, et al
    MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.
    Lung Cancer. 2018;118:111-118.
    PubMed     Text format     Abstract available


  328. LIU Y, Li Y, Ou Q, Wu X, et al
    Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Lung Cancer. 2018;118:1-5.
    PubMed     Text format     Abstract available


    March 2018
  329. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
    Lung Cancer. 2018 Mar 19. pii: S0169-5002(18)30301.
    PubMed     Text format    


  330. LI J, Wang Z, Groen HJM, Zhao J, et al
    Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
    Lung Cancer. 2018 Mar 1. pii: S0169-5002(18)30273.
    PubMed     Text format    


  331. GERBER DE, Socinski MA, Neal JW, Wakelee HA, et al
    Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
    Lung Cancer. 2018;117:44-49.
    PubMed     Text format     Abstract available


  332. SPIGEL DR, Hainsworth JD, Shipley DL, Mekhail TM, et al
    Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
    Lung Cancer. 2018;117:38-43.
    PubMed     Text format     Abstract available


  333. SCULIER JP, Lafitte JJ, Berghmans T, Meert AP, et al
    A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
    Lung Cancer. 2018;117:32-37.
    PubMed     Text format     Abstract available


  334. ZHANG B, Xu J, Zhang X, Gu P, et al
    Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
    Lung Cancer. 2018;117:27-31.
    PubMed     Text format     Abstract available


  335. YANG W, Qian F, Teng J, Wang H, et al
    Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening.
    Lung Cancer. 2018;117:20-26.
    PubMed     Text format     Abstract available


  336. OKAMOTO I, Morita S, Tashiro N, Imamura F, et al
    Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
    Lung Cancer. 2018;117:14-19.
    PubMed     Text format     Abstract available


  337. ARIYASU R, Nishikawa S, Uchibori K, Oh-Hara T, et al
    High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
    Lung Cancer. 2018;117:1-6.
    PubMed     Text format     Abstract available


  338. PARK BJ, Cho JH, Lee JH, Shin S, et al
    Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy.
    Lung Cancer. 2018;117:7-13.
    PubMed     Text format     Abstract available


    February 2018
  339. ODA K, Kato K, Nakamura M, Jotatsu T, et al
    Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab.
    Lung Cancer. 2018 Feb 21. pii: S0169-5002(18)30269.
    PubMed     Text format    


  340. BARUA S, Fang P, Sharma A, Fujimoto J, et al
    Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer.
    Lung Cancer. 2018 Feb 3. pii: S0169-5002(18)30236.
    PubMed     Text format     Abstract available


  341. VANDERLAAN PA, Rangachari D, Majid A, Parikh MS, et al
    Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
    Lung Cancer. 2018;116:90-95.
    PubMed     Text format     Abstract available


  342. CHENG CC, Chou KF, Wu CW, Su NW, et al
    EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.
    Lung Cancer. 2018;116:80-89.
    PubMed     Text format     Abstract available


  343. ARAN V, Masson Domingues P, Carvalho de Macedo F, Moreira de Sousa CA, et al
    A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients.
    Lung Cancer. 2018;116:7-14.
    PubMed     Text format     Abstract available


  344. GAUVAIN C, Vauleon E, Chouaid C, Lerhun E, et al
    Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.
    Lung Cancer. 2018;116:62-66.
    PubMed     Text format     Abstract available


  345. DRIESSEN EJM, Schulkes KJG, Dingemans AC, van Loon JGM, et al
    Patterns of treatment and survival among older patients with stage III non-small cell lung cancer.
    Lung Cancer. 2018;116:55-61.
    PubMed     Text format     Abstract available


  346. CUI S, Cheng Z, Qin W, Jiang L, et al
    Exosomes as a liquid biopsy for lung cancer.
    Lung Cancer. 2018;116:46-54.
    PubMed     Text format     Abstract available


  347. PARK KS, Moon YW, Raffeld M, Lee DH, et al
    High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.
    Lung Cancer. 2018;116:38-45.
    PubMed     Text format     Abstract available


  348. ARNEY J, Helm A, Crook T, Braun UK, et al
    Utilization of genomic testing in advanced non-small cell lung cancer among oncologists in the Veterans Health Administration.
    Lung Cancer. 2018;116:25-29.
    PubMed     Text format     Abstract available


  349. MCLEER-FLORIN A, Duruisseaux M, Pinsolle J, Dubourd S, et al
    ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2018;116:15-24.
    PubMed     Text format     Abstract available


  350. REMON J, Pardo N, Martinez-Marti A, Cedres S, et al
    Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75].
    Lung Cancer. 2018 Feb 1. pii: S0169-5002(17)30564.
    PubMed     Text format    


  351. PAAJANEN J, Laaksonen S, Ilonen I, Wolff H, et al
    Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
    Lung Cancer. 2018;116:73-79.
    PubMed     Text format     Abstract available


  352. QIN BD, Jiao XD, Zang YS
    Primary pulmonary leiomyosarcoma: A population-based study.
    Lung Cancer. 2018;116:67-72.
    PubMed     Text format     Abstract available


  353. ZHOU F, Hou L, Ding T, Song Q, et al
    Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
    Lung Cancer. 2018;116:30-37.
    PubMed     Text format     Abstract available


  354. TAKADA K, Toyokawa G, Tagawa T, Kohashi K, et al
    PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
    Lung Cancer. 2018;116:1-6.
    PubMed     Text format     Abstract available


  355. CHEN Y, Chen B, Zhu X, Zhong J, et al
    A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
    Lung Cancer. 2018;116:96-98.
    PubMed     Text format    


    January 2018
  356. GOROSPE L, Arrieta P, Ajuria-Illarramendi O, Barbolla-Diaz I, et al
    Pulmonary aspergilloma mimicking synchronous lung cancer on PET/CT in a patient with head and neck cancer.
    Lung Cancer. 2018 Jan 17. pii: S0169-5002(18)30018.
    PubMed     Text format    


  357. KHAN SA, Pruitt SL, Xuan L, Makris U, et al
    How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.
    Lung Cancer. 2018;115:97-102.
    PubMed     Text format     Abstract available


  358. LEE J, Kim HK, Park BJ, Cho JH, et al
    Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.
    Lung Cancer. 2018;115:89-96.
    PubMed     Text format     Abstract available


  359. TAN PS, Aguiar P Jr, Haaland B, Lopes G, et al
    Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Lung Cancer. 2018;115:84-88.
    PubMed     Text format     Abstract available


  360. YANG CJ, Gu L, Shah SA, Yerokun BA, et al
    Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis.
    Lung Cancer. 2018;115:75-83.
    PubMed     Text format     Abstract available


  361. SATO K, Akamatsu H, Murakami E, Sasaki S, et al
    Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Lung Cancer. 2018;115:71-74.
    PubMed     Text format     Abstract available


  362. HUANG HC, Su WJ, Chiang CL, Feng JY, et al
    The predictive value of the interferon-gamma release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2018;115:64-70.
    PubMed     Text format     Abstract available


  363. TOURNOY KG, Thomeer M, Germonpre P, Derijcke S, et al
    Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
    Lung Cancer. 2018;115:49-55.
    PubMed     Text format     Abstract available


  364. THAWANI R, McLane M, Beig N, Ghose S, et al
    Radiomics and radiogenomics in lung cancer: A review for the clinician.
    Lung Cancer. 2018;115:34-41.
    PubMed     Text format     Abstract available


  365. ISAKA M, Kojima H, Takahashi S, Omae K, et al
    Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy.
    Lung Cancer. 2018;115:28-33.
    PubMed     Text format     Abstract available


  366. EVISON M, Edwards T, Balata H, Tempowski A, et al
    Prevalence of nodal metastases in lymph node stations 8 & 9 in a large UK lung cancer surgical centre without routine pre-operative EUS nodal staging.
    Lung Cancer. 2018;115:127-130.
    PubMed     Text format     Abstract available


  367. SOO RA, Lim SM, Syn NL, Teng R, et al
    Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Lung Cancer. 2018;115:12-20.
    PubMed     Text format     Abstract available


  368. TANAKA K, Isse K, Fujihira T, Takenoyama M, et al
    Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
    Lung Cancer. 2018;115:116-120.
    PubMed     Text format     Abstract available


  369. LIU X, Jiang T, Li W, Li X, et al
    Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer.
    Lung Cancer. 2018;115:109-115.
    PubMed     Text format     Abstract available


  370. NINOMIYA T, Nogami N, Kozuki T, Harada D, et al
    A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Lung Cancer. 2018;115:103-108.
    PubMed     Text format     Abstract available


  371. NAKAMURA H, Ichikawa T, Nakasone S, Miyoshi T, et al
    Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
    Lung Cancer. 2018;115:56-63.
    PubMed     Text format     Abstract available


  372. JIANG J, Wu X, Tong X, Wei W, et al
    GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
    Lung Cancer. 2018;115:5-11.
    PubMed     Text format     Abstract available


  373. MIURA Y, Kaira K, Sakurai R, Sunaga N, et al
    High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
    Lung Cancer. 2018;115:42-48.
    PubMed     Text format     Abstract available


  374. MINARI R, Bordi P, Del Re M, Facchinetti F, et al
    Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
    Lung Cancer. 2018;115:21-27.
    PubMed     Text format     Abstract available


  375. GALLI G, Corrao G, Imbimbo M, Proto C, et al
    Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review.
    Lung Cancer. 2018;115:135-142.
    PubMed     Text format     Abstract available


  376. ZHU YC, Wang WX, Xu CW, Song ZB, et al
    EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
    Lung Cancer. 2018;115:131-134.
    PubMed     Text format     Abstract available


  377. ZHANG L, Belani CP, Zhang PH, Wang X, et al
    Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial.
    Lung Cancer. 2018;115:121-126.
    PubMed     Text format     Abstract available


  378. HORNE ZD, Richman AH, Dohopolski MJ, Clump DA, et al
    Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.
    Lung Cancer. 2018;115:1-4.
    PubMed     Text format     Abstract available


    December 2017
  379. LIU E, Guha A, Jia K, Ayers AM, et al
    Corrigendum to "Cardiogenic shock in a patient being treated with Atezolizumab for metastatic non-small cell lung cancer" [Lung Cancer, 114, (December) (2017) 106-107].
    Lung Cancer. 2017 Dec 29. pii: S0169-5002(17)30621.
    PubMed     Text format    


  380. VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
    Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49].
    Lung Cancer. 2017 Dec 27. pii: S0169-5002(17)30618.
    PubMed     Text format    


  381. GROSSI F, Genova C, Rijavec E, Barletta G, et al
    Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
    Lung Cancer. 2017 Dec 13. pii: S0169-5002(17)30614.
    PubMed     Text format     Abstract available


  382. TU HY, Ke EE, Yang JJ, Sun YL, et al
    A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
    Lung Cancer. 2017;114:96-102.
    PubMed     Text format     Abstract available


  383. TIAN HX, Zhang XC, Yang JJ, Guo WB, et al
    Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.
    Lung Cancer. 2017;114:90-95.
    PubMed     Text format     Abstract available


  384. SHEN J, Ye Y, Chang DW, Huang M, et al
    Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
    Lung Cancer. 2017;114:70-78.
    PubMed     Text format     Abstract available


  385. CHALMERS A, Jensen L, Akerley W
    Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.
    Lung Cancer. 2017;114:68-69.
    PubMed     Text format     Abstract available


  386. ZHU Y, Li T, Chen G, Yan G, et al
    Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p.
    Lung Cancer. 2017;114:6-11.
    PubMed     Text format     Abstract available


  387. KEUSTERS WR, de Weger VA, Hovels A, Schellens JHM, et al
    Changing costs of metastatic non small cell lung cancer in the Netherlands.
    Lung Cancer. 2017;114:56-61.
    PubMed     Text format     Abstract available


  388. VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
    Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2017;114:44-49.
    PubMed     Text format     Abstract available


  389. WANG X, Leader JK, Wang R, Wilson D, et al
    Vasculature surrounding a nodule: A novel lung cancer biomarker.
    Lung Cancer. 2017;114:38-43.
    PubMed     Text format     Abstract available


  390. ZANON M, Pacini GS, de Souza VVS, Marchiori E, et al
    Early detection of lung cancer using ultra-low-dose computed tomography in coronary CT angiography scans among patients with suspected coronary heart disease.
    Lung Cancer. 2017;114:1-5.
    PubMed     Text format     Abstract available


  391. HAN L, Lee CK, Pang H, Chan HT, et al
    Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status.
    Lung Cancer. 2017;114:79-89.
    PubMed     Text format     Abstract available


  392. YAMAUCHI Y, Safi S, Muley T, Warth A, et al
    C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
    Lung Cancer. 2017;114:62-67.
    PubMed     Text format     Abstract available


  393. KUIJVENHOVEN JC, Crombag L, Breen DP, van den Berk I, et al
    Esophageal ultrasound (EUS) assessment of T4 status in NSCLC patients.
    Lung Cancer. 2017;114:50-55.
    PubMed     Text format     Abstract available


  394. WANG L, Guo Q, Yu W, Qiao L, et al
    Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR.
    Lung Cancer. 2017;114:31-37.
    PubMed     Text format     Abstract available


  395. MATSUMURA Y, Suzuki H, Ohira T, Shiono S, et al
    Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Lung Cancer. 2017;114:23-30.
    PubMed     Text format     Abstract available


  396. FOY V, Schenk MW, Baker K, Gomes F, et al
    Targeting DNA damage in SCLC.
    Lung Cancer. 2017;114:12-22.
    PubMed     Text format     Abstract available


    November 2017
  397. DUDNIK E, Moskovitz M, Daher S, Shamai S, et al
    Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Lung Cancer. 2017 Nov 23. pii: S0169-5002(17)30582.
    PubMed     Text format     Abstract available


  398. SCHOUTEN RD, Muller M, de Gooijer CJ, Baas P, et al
    Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
    Lung Cancer. 2017 Nov 17. pii: S0169-5002(17)30569.
    PubMed     Text format    


  399. GOROSPE L, Garcia-Latorre R, Ajuria-Illarramendi O, Arrieta P, et al
    Lipoid pneumonia mimicking multifocal lung cancer in a patient with a remote laryngectomy and a recently diagnosed lung cancer: PET/CT findings.
    Lung Cancer. 2017 Nov 7. pii: S0169-5002(17)30560.
    PubMed     Text format    


  400. GOROSPE L, Sanchez-Monforte JC, Cabanas-Montero J, Arrieta P, et al
    Incidental retroperitoneal malignant solitary fibrous tumor detected at lung cancer screening with low-dose thoracic CT.
    Lung Cancer. 2017 Nov 6. pii: S0169-5002(17)30561.
    PubMed     Text format    


  401. AHMED Z, Grover P, Kennedy KF, Masood A, et al
    Predictors for chemotherapy in early stage small cell lung carcinoma (SCLC): A National Cancer Database (NCDB) analysis.
    Lung Cancer. 2017;113:85-87.
    PubMed     Text format    


  402. SPIGEL DR, Rubin MS, Gian VG, Shipley DL, et al
    Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
    Lung Cancer. 2017;113:79-84.
    PubMed     Text format     Abstract available


  403. KAWANO Y, Iwama E, Tsuchihashi K, Shibahara D, et al
    CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.
    Lung Cancer. 2017;113:72-78.
    PubMed     Text format     Abstract available


  404. KATO T, Jin CS, Ujiie H, Lee D, et al
    Nanoparticle targeted folate receptor 1-enhanced photodynamic therapy for lung cancer.
    Lung Cancer. 2017;113:59-68.
    PubMed     Text format     Abstract available


  405. HORN L, Gettinger S, Camidge DR, Smit EF, et al
    Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Lung Cancer. 2017;113:51-58.
    PubMed     Text format     Abstract available


  406. HEUVELMANS MA, Walter JE, Peters RB, Bock GH, et al
    Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study.
    Lung Cancer. 2017;113:45-50.
    PubMed     Text format     Abstract available


  407. HOCHMAIR MJ, Schwab S, Burghuber OC, Krenbek D, et al
    Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
    Lung Cancer. 2017;113:4-6.
    PubMed     Text format     Abstract available


  408. CORRALES-RODRIGUEZ L, Arrieta O, Mas L, Baez-Saldana R, et al
    An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP).
    Lung Cancer. 2017;113:30-36.
    PubMed     Text format     Abstract available


  409. LIU C, Cui H, Gu D, Zhang M, et al
    Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies.
    Lung Cancer. 2017;113:18-29.
    PubMed     Text format     Abstract available


  410. BOUAZZA YB, Chiairi I, El Kharbouchi O, De Backer L, et al
    Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review.
    Lung Cancer. 2017;113:140-151.
    PubMed     Text format     Abstract available


  411. SANTONI-RUGIU E, Grauslund M, Melchior LC, Costa JC, et al
    Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Lung Cancer. 2017;113:14-17.
    PubMed     Text format     Abstract available


  412. ICHIKAWA T, Saruwatari K, Mimaki S, Sugano M, et al
    Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.
    Lung Cancer. 2017;113:134-139.
    PubMed     Text format     Abstract available


  413. SCHMIDT LH, Stucke-Ring J, Brand C, Schliemann C, et al
    CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
    Lung Cancer. 2017;113:121-127.
    PubMed     Text format     Abstract available


  414. TALBOT T, Dangoor A, Shah R, Naik J, et al
    The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
    Lung Cancer. 2017;113:115-120.
    PubMed     Text format     Abstract available


  415. LEE CK, Kim S, Lee JS, Lee JE, et al
    Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lung Cancer. 2017;113:106-114.
    PubMed     Text format     Abstract available


  416. HASSAN A, Latif MT, Soo CI, Faisal AH, et al
    Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods.
    Lung Cancer. 2017;113:1-3.
    PubMed     Text format     Abstract available


    October 2017
  417. SAWA K, Koh Y, Kawaguchi T, Kambayashi S, et al
    PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
    Lung Cancer. 2017;112:96-101.
    PubMed     Text format     Abstract available


  418. SCHVARTSMAN G, Peng SA, Bis G, Lee JJ, et al
    Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Lung Cancer. 2017;112:90-95.
    PubMed     Text format     Abstract available


  419. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
    Lung Cancer. 2017;112:81-89.
    PubMed     Text format     Abstract available


  420. HE Y, Rozeboom L, Rivard CJ, Ellison K, et al
    MHC class II expression in lung cancer.
    Lung Cancer. 2017;112:75-80.
    PubMed     Text format     Abstract available


  421. ROS-MAZURCZYK M, Jelonek K, Marczyk M, Binczyk F, et al
    Serum lipid profile discriminates patients with early lung cancer from healthy controls.
    Lung Cancer. 2017;112:69-74.
    PubMed     Text format     Abstract available


  422. FACCHINETTI F, Bluthgen MV, Tergemina-Clain G, Faivre L, et al
    LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Lung Cancer. 2017;112:62-68.
    PubMed     Text format     Abstract available


  423. TOMIZAWA K, Shimizu S, Ohara S, Fujino T, et al
    Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer.
    Lung Cancer. 2017;112:57-61.
    PubMed     Text format     Abstract available


  424. LEFRESNE S, Olson R, Cashman R, Kostuik P, et al
    Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic.
    Lung Cancer. 2017;112:35-40.
    PubMed     Text format     Abstract available


  425. NISHIE K, Yamamoto S, Nagata C, Koizumi T, et al
    Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
    Lung Cancer. 2017;112:25-34.
    PubMed     Text format     Abstract available


  426. KUYAMA S, Ochi N, Bessho A, Hotta K, et al
    A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
    Lung Cancer. 2017;112:188-194.
    PubMed     Text format     Abstract available


  427. RECK M, Paz-Ares L, Bidoli P, Cappuzzo F, et al
    Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
    Lung Cancer. 2017;112:181-187.
    PubMed     Text format     Abstract available


  428. QIN N, Wang C, Zhu M, Lu Q, et al
    Fine-mapping the MHC region in Asian populations identified novel variants modifying susceptibility to lung cancer.
    Lung Cancer. 2017;112:169-175.
    PubMed     Text format     Abstract available


  429. LARA JD, Brunson A, Riess JW, Kelly K, et al
    Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.
    Lung Cancer. 2017;112:165-168.
    PubMed     Text format     Abstract available


  430. VINOD SK, Chandra A, Berthelsen A, Descallar J, et al
    Does timeliness of care in Non-Small Cell Lung Cancer impact on survival?
    Lung Cancer. 2017;112:16-24.
    PubMed     Text format     Abstract available


  431. JACOBSEN MM, Silverstein SC, Quinn M, Waterston LB, et al
    Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review.
    Lung Cancer. 2017;112:156-164.
    PubMed     Text format     Abstract available


  432. EL ZOGHBI M, Salameh P, Stucker I, Paris C, et al
    Phenotypes of lung cancer and statistical interactions between tobacco smoking and occupational exposure to asbestos and crystalline silica from a large case-only study: The CaProMat study.
    Lung Cancer. 2017;112:140-155.
    PubMed     Text format     Abstract available


  433. KWINT M, Walraven I, Burgers S, Hartemink K, et al
    Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.
    Lung Cancer. 2017;112:134-139.
    PubMed     Text format     Abstract available


  434. PAZ-ARES LG, Perol M, Ciuleanu TE, Kowalyszyn RD, et al
    Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
    Lung Cancer. 2017;112:126-133.
    PubMed     Text format     Abstract available


  435. AGGARWAL C, Wang X, Ranganathan A, Torigian D, et al
    Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
    Lung Cancer. 2017;112:118-125.
    PubMed     Text format     Abstract available


  436. SNOECKX A, Dendooven A, Carp L, Desbuquoit D, et al
    Wolf in Sheep's Clothing: Primary Lung Cancer Mimicking Benign Entities.
    Lung Cancer. 2017;112:109-117.
    PubMed     Text format     Abstract available


  437. MEZQUITA L, Charrier M, Faivre L, Dupraz L, et al
    Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.
    Lung Cancer. 2017;112:10-15.
    PubMed     Text format     Abstract available


    September 2017
  438. ROUSSEAU-GAZANIOL C, Fraboulet S, Couderc LJ, Kreis H, et al
    Lung cancer in renal transplant recipients: A case-control study.
    Lung Cancer. 2017;111:96-100.
    PubMed     Text format     Abstract available


  439. MIURA K, Hamanaka K, Koizumi T, Kitaguchi Y, et al
    Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: Comparative study of normal lung, emphysema, and pulmonary fibrosis.
    Lung Cancer. 2017;111:88-95.
    PubMed     Text format     Abstract available


  440. LIM SM, Chang H, Cha YJ, Liang S, et al
    Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lung Cancer. 2017;111:79-83.
    PubMed     Text format     Abstract available


  441. MOON SM, Lee DG, Hwang NY, Ahn S, et al
    Ipsilateral pleural recurrence after diagnostic transthoracic needle biopsy in pathological stage I lung cancer patients who underwent curative resection.
    Lung Cancer. 2017;111:69-74.
    PubMed     Text format     Abstract available


  442. TOKACA N, Wotherspoon A, Nicholson AG, Fotiadis N, et al
    Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
    Lung Cancer. 2017;111:65-68.
    PubMed     Text format     Abstract available


  443. CAPELAN M, Roda D, Geuna E, Rihawi K, et al
    Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
    Lung Cancer. 2017;111:6-11.
    PubMed     Text format     Abstract available


  444. CALIFANO R, Greystoke A, Lal R, Thompson J, et al
    Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Lung Cancer. 2017;111:51-58.
    PubMed     Text format     Abstract available


  445. SHEN L, Niu X, Jian H, Xu Y, et al
    Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;111:43-50.
    PubMed     Text format     Abstract available


  446. MORIKAWA N, Inoue A, Sugawara S, Maemondo M, et al
    Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naive extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Lung Cancer. 2017;111:38-42.
    PubMed     Text format     Abstract available


  447. GOBBINI E, Galetta D, Tiseo M, Graziano P, et al
    Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
    Lung Cancer. 2017;111:30-37.
    PubMed     Text format     Abstract available


  448. LABBE C, Cabanero M, Korpanty GJ, Tomasini P, et al
    Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Lung Cancer. 2017;111:23-29.
    PubMed     Text format     Abstract available


  449. HATA A, Katakami N, Nanjo S, Okuda C, et al
    Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2017;111:182-189.
    PubMed     Text format     Abstract available


  450. DIEM S, Schmid S, Krapf M, Flatz L, et al
    Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Lung Cancer. 2017;111:176-181.
    PubMed     Text format     Abstract available


  451. SCULIER C, Bentea G, Ruelle L, Grigoriu B, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions.
    Lung Cancer. 2017;111:164-175.
    PubMed     Text format     Abstract available


  452. RUELLE L, Bentea G, Sideris S, El Koulali M, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles.
    Lung Cancer. 2017;111:150-163.
    PubMed     Text format     Abstract available


  453. WOHLKOENIG C, Leithner K, Olschewski A, Olschewski H, et al
    TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1alpha.
    Lung Cancer. 2017;111:15-22.
    PubMed     Text format     Abstract available


  454. YOUSAF-KHAN AU, van der Aalst CM, Aerts JGJV, den Bakker MA, et al
    Uniform and blinded cause of death verification of the NELSON lung cancer screening participants.
    Lung Cancer. 2017;111:131-134.
    PubMed     Text format     Abstract available


  455. GAGLIASSO M, Migliaretti G, Ardissone F
    Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery.
    Lung Cancer. 2017;111:124-130.
    PubMed     Text format     Abstract available


  456. TAGHIZADEH N, Taylor KL, MacEachern P, Koetzler R, et al
    Tobacco use and motivation to stop smoking among long-term smokers who are ineligible for lung cancer screening.
    Lung Cancer. 2017;111:101-107.
    PubMed     Text format     Abstract available


  457. FUJIMOTO D, Morimoto T, Ito J, Sato Y, et al
    A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
    Lung Cancer. 2017;111:1-5.
    PubMed     Text format     Abstract available


    August 2017
  458. VON VERSCHUER U, Schnell R, Tessen HW, Eggert J, et al
    Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
    Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419.
    PubMed     Text format     Abstract available


  459. CHENG YW, Chiou HL, Chen JT, Chou MC, et al
    Corrigendum to: 'Gender difference in human papillomarvirus infection for non-small cell lung cancer in Taiwan' [Lung Cancer 46 (November(2)) (2004) 165-170].
    Lung Cancer. 2017 Aug 18. pii: S0169-5002(17)30486.
    PubMed     Text format    


  460. LIAO BC, Lin CC, Lee JH, Yang JC, et al
    Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Lung Cancer. 2017;110:7-13.
    PubMed     Text format     Abstract available


  461. KIM EY, Kim A, Kim SK, Chang YS, et al
    MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
    Lung Cancer. 2017;110:63-67.
    PubMed     Text format     Abstract available


  462. KIM SH, Hyun JW, Kim HJ, Gwak HS, et al
    De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer.
    Lung Cancer. 2017;110:53-55.
    PubMed     Text format     Abstract available


  463. TAO MH, Dai Q, Chen S, Freudenheim JL, et al
    Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative.
    Lung Cancer. 2017;110:42-47.
    PubMed     Text format     Abstract available


  464. KOBAYASHI-WATANABE N, Sato A, Watanabe T, Abe T, et al
    Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
    Lung Cancer. 2017;110:35-41.
    PubMed     Text format     Abstract available


  465. SANDS J, Li Q, Hornberger J
    Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
    Lung Cancer. 2017;110:19-25.
    PubMed     Text format     Abstract available


  466. DICKHOFF C, Dahele M, Smit EF, Paul MA, et al
    Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry.
    Lung Cancer. 2017;110:14-18.
    PubMed     Text format     Abstract available


    July 2017
  467. LIU E, Guha A, Bertino E, Franco V, et al
    Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer.
    Lung Cancer. 2017 Jul 29. pii: S0169-5002(17)30416.
    PubMed     Text format    


  468. SCHONEWOLF CA, Verma V, Post CM, Berman AT, et al
    Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Lung Cancer. 2017 Jul 14. pii: S0169-5002(17)30384.
    PubMed     Text format     Abstract available


  469. TAMURA T, Takagi Y, Okubo H, Yamaguchi S, et al
    Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis.
    Lung Cancer. 2017 Jul 8. pii: S0169-5002(17)30386.
    PubMed     Text format    


  470. YOSHIDA T, Kuroda H, Oya Y, Shimizu J, et al
    Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Lung Cancer. 2017;109:89-91.
    PubMed     Text format     Abstract available


  471. WAKEAM E, Acuna SA, Leighl NB, Giuliani ME, et al
    Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival.
    Lung Cancer. 2017;109:78-88.
    PubMed     Text format     Abstract available


  472. LOPEZ-PASTORINI A, Riedel R, Koryllos A, Beckers F, et al
    The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer.
    Lung Cancer. 2017;109:68-73.
    PubMed     Text format     Abstract available


  473. ERIGUCHI T, Takeda A, Sanuki N, Tsurugai Y, et al
    Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
    Lung Cancer. 2017;109:62-67.
    PubMed     Text format     Abstract available


  474. FUJISHITA T, Okamoto T, Akamine T, Takamori S, et al
    Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer.
    Lung Cancer. 2017;109:52-57.
    PubMed     Text format     Abstract available


  475. GAO SJ, Kim AW, Puchalski JT, Bramley K, et al
    Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT.
    Lung Cancer. 2017;109:36-41.
    PubMed     Text format     Abstract available


  476. ZIEMKE M, Patil T, Nolan K, Tippimanchai D, et al
    Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
    Lung Cancer. 2017;109:28-35.
    PubMed     Text format     Abstract available


  477. O'KANE GM, Bradbury PA, Feld R, Leighl NB, et al
    Uncommon EGFR mutations in advanced non-small cell lung cancer.
    Lung Cancer. 2017;109:137-144.
    PubMed     Text format     Abstract available


  478. WAKEAM E, Varghese TK Jr, Leighl NB, Giuliani M, et al
    Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer.
    Lung Cancer. 2017;109:117-123.
    PubMed     Text format     Abstract available


  479. SUDA K, Rozeboom L, Rivard CJ, Yu H, et al
    Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
    Lung Cancer. 2017;109:1-8.
    PubMed     Text format     Abstract available


  480. DURUISSEAUX M, Antoine M, Rabbe N, Rodenas A, et al
    Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
    Lung Cancer. 2017;109:92-100.
    PubMed     Text format     Abstract available


  481. DEARDEN S, Brown H, Jenkins S, Thress KS, et al
    EGFR T790M mutation testing within the osimertinib AURA Phase I study.
    Lung Cancer. 2017;109:9-13.
    PubMed     Text format     Abstract available


  482. RASKIN J, Masrori P, Cant A, Snoeckx A, et al
    Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
    Lung Cancer. 2017;109:74-77.
    PubMed     Text format     Abstract available


  483. ITO J, Fujimoto D, Nakamura A, Nagano T, et al
    Aprepitant for refractory nivolumab-induced pruritus.
    Lung Cancer. 2017;109:58-61.
    PubMed     Text format     Abstract available


  484. YOTSUKURA M, Yasuda H, Shigenobu T, Kaseda K, et al
    Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
    Lung Cancer. 2017;109:45-51.
    PubMed     Text format     Abstract available


  485. UENAMI T, Hosono Y, Ishijima M, Kanazu M, et al
    Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
    Lung Cancer. 2017;109:42-44.
    PubMed     Text format     Abstract available


  486. ZHANG L, Li S, Choi YL, Lee J, et al
    Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq.
    Lung Cancer. 2017;109:21-27.
    PubMed     Text format     Abstract available


  487. BOLAND JM, Wampfler JA, Yang P, Yi ES, et al
    Growth pattern-based grading of pulmonary adenocarcinoma-Analysis of 534 cases with comparison between observers and survival analysis.
    Lung Cancer. 2017;109:14-20.
    PubMed     Text format     Abstract available


  488. HERRERA-MARTINEZ AD, Gahete MD, Sanchez-Sanchez R, Salas RO, et al
    The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features.
    Lung Cancer. 2017;109:128-136.
    PubMed     Text format     Abstract available


  489. ZHU YJ, Zhang HB, Liu YH, Zhang FL, et al
    Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients.
    Lung Cancer. 2017;109:124-127.
    PubMed     Text format     Abstract available


  490. ZHANG L, Li J, Hu J, Li D, et al
    Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
    Lung Cancer. 2017;109:109-116.
    PubMed     Text format     Abstract available


  491. GADGEEL S, Goss G, Soria JC, Felip E, et al
    Evaluation of the VeriStrat((R)) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
    Lung Cancer. 2017;109:101-108.
    PubMed     Text format     Abstract available


    June 2017
  492. GOROSPE L, Rioja-Martin ME, Santos-Carreno AL, Pacios-Blanco RE, et al
    Supraclavicular schwannoma mimicking a lymphadenopathy in a lung cancer patient: PET/CT findings.
    Lung Cancer. 2017 Jun 8. pii: S0169-5002(17)30354.
    PubMed     Text format    


  493. ZHAO J, Guerrero A, Kelnar K, Peltier HJ, et al
    Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
    Lung Cancer. 2017;108:96-102.
    PubMed     Text format     Abstract available


  494. GREENBERG V, Lazarev I, Frank Y, Dudnik J, et al
    Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?
    Lung Cancer. 2017;108:90-95.
    PubMed     Text format     Abstract available


  495. IMPERATORI A, Sahnane N, Rotolo N, Franzi F, et al
    LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
    Lung Cancer. 2017;108:83-89.
    PubMed     Text format     Abstract available


  496. HIDAKA N, Iwama E, Kubo N, Harada T, et al
    Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
    Lung Cancer. 2017;108:75-82.
    PubMed     Text format     Abstract available


  497. GION M, Remon J, Caramella C, Soria JC, et al
    Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
    Lung Cancer. 2017;108:72-74.
    PubMed     Text format     Abstract available


  498. NIHO S, Ohe Y, Ohmatsu H, Umemura S, et al
    Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
    Lung Cancer. 2017;108:66-71.
    PubMed     Text format     Abstract available


  499. MCEVOY SH, Halpenny DF, Viteri-Jusue A, Hayes SA, et al
    Investigation of patterns of nodal metastases in BRAF mutant lung cancer.
    Lung Cancer. 2017;108:62-65.
    PubMed     Text format     Abstract available


  500. YU XQ, Luo Q, Kahn C, Grogan P, et al
    Contrasting temporal trends in lung cancer incidence by socioeconomic status among women in New South Wales, Australia, 1985-2009.
    Lung Cancer. 2017;108:55-61.
    PubMed     Text format     Abstract available


  501. CROMBAG LMMJ, Szlubowski A, Stigt JA, Schuurbiers O, et al
    EUS-B-FNA vs conventional EUS-FNA for left adrenal gland analysis in lung cancer patients.
    Lung Cancer. 2017;108:38-44.
    PubMed     Text format     Abstract available


  502. SEKINE I, Harada H, Yamamoto N, Wakabayashi M, et al
    Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
    Lung Cancer. 2017;108:232-237.
    PubMed     Text format     Abstract available


  503. KOSHY M, Malik R, Spiotto M, Mahmood U, et al
    Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
    Lung Cancer. 2017;108:222-227.
    PubMed     Text format     Abstract available


  504. RUIZ-BANOBRE J, Perez-Pampin E, Garcia-Gonzalez J, Gomez-Caamano A, et al
    Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
    Lung Cancer. 2017;108:217-221.
    PubMed     Text format     Abstract available


  505. WEHLER T, Thomas M, Schumann C, Bosch-Barrera J, et al
    A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
    Lung Cancer. 2017;108:212-216.
    PubMed     Text format     Abstract available


  506. DRIESSEN EJ, Aarts MJ, Bootsma GP, van Loon JG, et al
    Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients.
    Lung Cancer. 2017;108:198-204.
    PubMed     Text format     Abstract available


  507. YANG SC, Lai WW, Lin CC, Su WC, et al
    Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
    Lung Cancer. 2017;108:183-191.
    PubMed     Text format     Abstract available


  508. HARRIS JP, Patel MI, Loo BW, Wakelee HA, et al
    A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.
    Lung Cancer. 2017;108:173-182.
    PubMed     Text format     Abstract available


  509. MORAN T, Palmero R, Provencio M, Insa A, et al
    A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
    Lung Cancer. 2017;108:154-160.
    PubMed     Text format     Abstract available


  510. MORABITO A, Daniele G, Costanzo R, Favaretto AG, et al
    A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
    Lung Cancer. 2017;108:15-21.
    PubMed     Text format     Abstract available


  511. PATEL MI, McKinley M, Cheng I, Haile R, et al
    Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years.
    Lung Cancer. 2017;108:140-149.
    PubMed     Text format     Abstract available


  512. KRON F, Kostenko A, Scheffler M, Muller D, et al
    Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center.
    Lung Cancer. 2017;108:134-139.
    PubMed     Text format     Abstract available


  513. KANAJI N, Sakai K, Ueda Y, Miyawaki H, et al
    Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
    Lung Cancer. 2017;108:126-133.
    PubMed     Text format     Abstract available


  514. PATEL SH, Rimner A, Foster A, Zhang Z, et al
    Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
    Lung Cancer. 2017;108:109-114.
    PubMed     Text format     Abstract available


  515. MIKUBO M, Nakashima H, Naito M, Matsui Y, et al
    Prognostic impact of uncertain parietal pleural invasion at adhesion sites in non-small cell lung cancer patients.
    Lung Cancer. 2017;108:103-108.
    PubMed     Text format     Abstract available


    April 2017
  516. SIMMONS CP, Koinis F, Fallon MT, Fearon KC, et al
    Corrigendum to "Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors" [Lung Cancer 88 (2015) 304-309].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(17)30302.
    PubMed     Text format    


  517. TANAKA N, Toyooka S, Soh J, Kubo T, et al
    Erratum to "Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer" [Lung Cancer 76 (1) (2012) 32-38].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(16)30299.
    PubMed     Text format    


  518. EDWARDS T, Balata H, Foden P, Crosbie P, et al
    Research letter: Evaluating the future pathological N descriptors for lung cancer staging in a UK population.
    Lung Cancer. 2017 Apr 15. pii: S0169-5002(17)30295.
    PubMed     Text format    


  519. METRO G, Tazza M, Matocci R, Chiari R, et al
    Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Lung Cancer. 2017;106:58-66.
    PubMed     Text format     Abstract available


  520. BASLER L, Kroeze SG, Guckenberger M
    SBRT for oligoprogressive oncogene addicted NSCLC.
    Lung Cancer. 2017;106:50-57.
    PubMed     Text format     Abstract available


  521. VANDERLAAN PA, Rangachari D, Mockus SM, Spotlow V, et al
    Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    Lung Cancer. 2017;106:17-21.
    PubMed     Text format     Abstract available


  522. KWON D, Koh J, Kim S, Go H, et al
    MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Lung Cancer. 2017;106:131-137.
    PubMed     Text format     Abstract available


  523. HONG SW, Park NS, Noh MH, Shim JA, et al
    Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
    Lung Cancer. 2017;106:115-124.
    PubMed     Text format     Abstract available


    March 2017
  524. LI H, Yang T, Ning Q, Shang D, et al
    MicroRNA-505 modulates cancer proliferation and migration in human non-small cell lung cancer through inverse regulation of FZD4.
    Lung Cancer. 2017 Mar 31. pii: S0169-5002(17)30270.
    PubMed     Text format     Abstract available


  525. CAPELLETTO E, Mariniello A, Novello S
    Targeted therapy in small cell lung cancer: A new era?
    Lung Cancer. 2017 Mar 12. pii: S0169-5002(17)30258.
    PubMed     Text format    


    February 2017
  526. HIDA T, Hamasaki M, Matsumoto S, Sato A, et al
    Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Lung Cancer. 2017;104:98-105.
    PubMed     Text format     Abstract available


  527. SAKAGUCHI H, Ishida H, Nitanda H, Yamazaki N, et al
    Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
    Lung Cancer. 2017;104:70-74.
    PubMed     Text format     Abstract available


  528. TAKADA K, Okamoto T, Toyokawa G, Kozuma Y, et al
    The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Lung Cancer. 2017;104:7-15.
    PubMed     Text format     Abstract available


  529. LAURIE SA, Hao D, Leighl NB, Goffin J, et al
    A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
    Lung Cancer. 2017;104:65-69.
    PubMed     Text format     Abstract available


  530. WU YL, Saijo N, Thongprasert S, Yang JC, et al
    Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Lung Cancer. 2017;104:119-125.
    PubMed     Text format     Abstract available


    January 2017
  531. TO KK, Tong WS, Fu LW
    Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    Lung Cancer. 2017;103:58-65.
    PubMed     Text format     Abstract available


  532. TSIM S, Stobo DB, Alexander L, Kelly C, et al
    The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy.
    Lung Cancer. 2017;103:38-43.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: